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Lung cancer is the deadliest and most common malignancy worldwide. Tumor invasion 
and metastasis influence the dismal 16% overal 5-year survival. Evidence suggests that 
malignancies commandeer epithelial plasticity programs (i.e. the epithelial-mesenchymal 
transition [EMT]) to promote tumorigenesis, tumor progression, and metastasis. However, 
recent evidence suggests there may be diverse roles of EMT beyond metastasis, such as 
chemoresistance. Furthermore, EMT may orchestrate cancer metabolic reprogramming, 
engendering adaptation to environmental stress while supporting the macromolecular 
demand of the cancer cel’s rapid proliferation. Specificaly, the role of protein 
glycosylation in cancer is becoming of increased interest, as novel technologies are being 
developed to study these unique post-translational modifications. Understanding these 
modifications in cancer provides more insight into mechanisms of the disease, 
complementing our existing knowledge of the genomic and proteomic alterations of 
cancer. 
 
SNAI1 and TWIST1 are two master EMT regulators and are often aberantly 
overexpressed in many cancers. To investigate the role of EMT in tumorigenesis, we 
created novel inducible autochthonous mouse models. Our models reveal that EMT-
driven mutant Kras mice generate tumors more rapidly than mice overexpressing mutant 
Kras alone. With these useful models, we identified significantly altered gene signatures 
related to metabolic reprogramming driven by the EMT. Specificaly, EMT upregulates 
the hexosamine biosynthetic pathway (HBP) in mutant Kras-driven mouse lung tumors. 
Here we show EMT promotes flux through the HBP to promote increased total levels of 
	 ii	
O-GlcNAcylated proteins in lung tumors in vivo. The role of O-GlcNAcylation in 
tumorigenesis has recently been gaining traction, as half of the body of literature on O-
GlcNAcylation and cancer has been published in the past three years. Together, the data 
in this thesis suggest a novel EMT-HBP axis that elevates the levels of protein O-
GlcNAcylation to accelerate mutant Kras-induced lung tumorigenesis and progression. 
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Chapter 1: Background and relevant literature 
1.1 Introduction 
The epithelial-mesenchymal transition (EMT) is a highly conserved program necessary 
for orchestrating distant cel migration during embryonic development. Multiple studies 
in cancer have demonstrated a critical role for EMT during the initial stages of 
tumorigenesis and later during tumor invasion. Transcription factors (TFs) such as 
SNAIL, TWIST, and ZEB are master EMT regulators that are aberantly overexpressed 
in many malignancies. Recent evidence corelates EMT-related transcriptomic alterations 
with metabolic reprogramming in cancer. Metabolic alterations may alow cancer to 
adapt to environmental stressors, supporting the iregular demand for macromolecules 
during periods of rapid proliferation. One potential metabolic pathway of increasing 
importance is the hexosamine biosynthesis pathway (HBP). The HBP utilizes glycolytic 
intermediates to generate the metabolite UDP-GlcNAc. This and other charged 
nucleotide sugars serve as the basis for biosynthesis of glycoproteins and other 
glycoconjugates. Recent reports in the field of glycobiology have cultivated great 
curiosity within the cancer research community. However, specific mechanistic 
relationships between the HBP and fundamental pathways of cancer, such as EMT, have 
yet to be elucidated. Altered protein glycosylation downstream of the HBP is wel 
positioned to mediate many celular changes associated with EMT including cel-cel 
adhesion, responsiveness to growth factors, immune system evasion, and signal 
transduction programs. Here we outline some of the basics of the HBP and putative roles 
the HBP may have in driving EMT-related cancer processes. With novel appreciation of 
the connection between HBP and EMT, we hope to iluminate the potential for new 
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therapeutic targets of cancer. 
 
1.2 Connecting metabolism to epithelial plasticity 
 
1.2.1 History of glucose metabolism in cancer 
Since the time of Oto Warburg in the 1930s, scientists have been intrigued by the unique 
metabolic profile of cancer cels 1,2. Curent research coroborates Warburg’s original 
observation that cancer cels utilize glycolysis over mitochondrial oxidative 
phosphorylation (OXPHOS) 3, even when oxygen is not limiting. Initialy, this metabolic 
reprogramming appeared paradoxical due to the ineficiencies of glycolysis (i.e., ~38 
ATP from OXPHOS versus 2 ATP from glycolysis). Despite early conflicting viewpoints 
on the Warburg Efect, aerobic glycolysis stands at the center of cancer metabolism 
demonstrating its importance as an “Emerging Halmark of Cancer” 4. 
 
Despite  decades  of research, the  molecular advantages  of the  Warburg efect in cancer 
are stil  being interogated 5.  One  popular explanation is the “Glycolytic Intermediate 
Diversion”  hypothesis 6,7.  This  hypothesis suggests that  glycolysis is  wel  positioned to 
support anabolic cel growth as it provides the metabolic intermediates (e.g., nucleosides, 
amino acids, and  other carbon compounds)  necessary for enzymatic reactions and 
organele assembly. A second hypothesis involves the notion of “Cel Subpopulations” 8–
10. This hypothesis posits lactate from “Warburg-efect cels” is sent to neighboring cels, 
which utilize lactate through the citric acid cycle. The cel subpopulations symbioticaly 
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trade of waste for energy to support cancer progression. Interestingly, both hypotheses 
demonstrate the ability of the neoplastic state to commandeer normal biological processes 
observed in development and normal physiology 4. 
1.2.2 Cancer metabolism and glycosylation overview 
The energetic  demand required to survive adverse tumor environments is likely  only a 
fraction of the functional significance underlying cancer metabolic reprogramming. It is 
likely that  glycolytic  byproducts reinforce the cancer  phenotype  by  modulating  not just 
metabolic maintenance, but altering other celular structures and functions. In particular, 
the role  of  post-translational  modifications (PTM), such as  glycosylation, are  becoming 
of increasing appreciation as they  provide rapid, reversible adaptations to the stressors 
that occur during early tumorigenesis. Recent studies have revealed new potential cancer 
treatment strategies specificaly targeting these glycoconjugates 11. 
 
Interestingly,  one  metabolic  pathway  with the  potential  of impacting functional 
macromolecular structures in cancer is an understudied pathway caled the “hexosamine 
biosynthetic pathway” (HBP) 12–15. One downstream metabolite of this pathway, Uridine 
diphosphate N-acetylglucosamine (UDP-GlcNAc), serves as an essential  building  block 
for  glycoconjugate  biosynthesis.  This  pathway is  wel  positioned to  not  only afect 
metabolic intermediates,  but also functional  glycans that accelerate cancer  progression 
11,16.  The  HBP  has  only recently  gained traction in cancer  biology and is  becoming  of 




1.2.3 Cancer epithelial plasticity overview 
The epithelial-mesenchymal transition (EMT) is a conserved epithelial plasticity program 
capable  of impacting celular  morphology,  migration, stem cel-ness, among  other 
malignant phenotypes 18. Moreover, the EMT is involved throughout the natural history 
of cancer from tumorigenesis to late  metastatic  progression 19–21.  Master transcriptional 
regulators  of  EMT (i.e., TWIST,  SNAIL, and  ZEB) are elevated in a  wide range  of 
primary and metastatic tumors. Recent evidence demonstrates that the expression of key 
enzymes in the  HBP are  upregulated in cancer cels  with a  mesenchymal  phenotype 22. 
Thus, in this review we wil highlight some of the relevant glycoconjugates downstream 
of the HBP and the implications this has on EMT-mediated cancer programs. 
 
1.3 The epithelial-mesenchymal transition (EMT) 
 
1.3.1 EMT functions and signaling pathways 
EMT is an essential epithelial  plasticity  program  deployed  during  development 23,24, 
wound healing 25–27, and stem cel maintenance 28–31. The major characteristics of EMT 
include loss of celular adhesion, reorganization of cytoskeleton, loss of celular polarity, 
and a switch from epithelial to  mesenchymal paterns  of gene expression 18.  Many  of 
these EMT pathways are activated by extracelular signaling, highlighting the importance 
of the tumor  microenvironment for the induction  of  EMT. Figure  1A outlines eight 
critical EMT-activating pathways: TGF-β, Receptor Tyrosine Kinases (RTKs), Integrin, 




 (Tapara, Frontiers in Oncology, 2016) 
 
 
Figure 1.1  Molecular pathways and targets of the epithelial–mesenchymal 
transition. 
 
(A) (1) One of the most wel characterized EMT-inducing pathways is the transforming 
growth factor-β (TGF-β) family receptors that activate downstream PI3K–AKT, ERK 
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MAPK, p38 MAPK, and JUN N-terminal kinase (JNK) pathways (activating pathways in 
blue; inactivating pathways in red). (2) The RAS–RAF–MEK–ERK MAPK pathway lies 
downstream of a number of growth factor activated receptor tyrosine kinases (RTKs) and 
activates a number of major EMT transcription factors (TFs). (3) Integrin signaling can 
have a multipronged efect on EMT by both interupting critical epithelial adhesion 
molecules (e.g., E-cadherin) and antagonizing GSK3-β via the integrin-linked kinase 
(ILK)-AKT signaling, thus promoting EMT. (4) WNT signaling can also interfere with 
GSK3-β, thus stabilizing β-catenin to promote EMT transcriptional programs in 
cooperation with lymphoid enhancer-binding factor 1 (LEF1) and T-cel factor (TCF). (5) 
The Hedgehog (HH)-glioma 1 (GLI1) and (6) NOTCH pathway both can promote 
transcription of the EMT regulators. (7) Recently, a number of inflammatory pathways 
downstream of interleukin (IL) signaling (e.g., IL-6) have demonstrated the activation of 
the Janus-kinase (JAK)-signal transducer and activator of transcription 3 (STAT3) 
pathway, which in turn promotes EMT transcription factors. (8) Hypoxia activates a 
number of key components of EMT through the hypoxia-induced factor 1 (HIF1α). (B) 
Downstream of these signal transduction pathways leading to EMT are a variety of 
transcription factors that determine the patern of gene expression. As an epithelial 
plasticity program, many of the target genes altered include adhesion molecules. Known 
glycosylated proteins involved with EMT are denoted with an asterisk (*).  
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1.3.2 EMT transcription factors (TFs) 
There are three major families of transcription factors (TFs) that contribute to EMT and 
may also  be  general  drivers  of cancer (Figure  1B):  1) the zinc finger  protein  SNAIL 
family (SNAI1, SNAI2, and SNAI3) 32,  2) the  basic  Helix-Loop-Helix (bHLH)  proteins 
TWIST1 and  TWIST2 33, and  3) the zinc-finger  E-box  binding (ZEB) family  of 
transcription factors 34.  These transcription factors are evolutionarily conserved and 
critical for  development.  They  bind short  DNA segments caled  Enhancer  boxes (E-
boxes)  with the consensus sequence “CANNTG”.  Like  many transcription factors, they 
are able to modulate transcription by recruiting a variety of epigenetic regulators to alter 
the chromatin landscape of epithelial plasticity genes and interactions with transcriptional 
co-activators and co-repressors 35. 
 
The most wel established gene targets of EMT TFs are generaly involved in epithelial 
cel adhesion 36–38. Cadherins represent a family of calcium-dependent cel-cel adhesion 
proteins particularly targeted by EMT 39–41. Loss of epithelial cadherin (E-cadherin) is a 
major halmark of EMT 42–44. Thus, loss of E-cadherin has been used as a biomarker for 
many cancers.  Additionaly, loss  of tight junctions (e.g., claudin and  occludin), 
desmosomes (e.g.,  desmoplakin and  plakophilin), and cytokeratins (intermediate 
filaments) are commonly observed during EMT 18. Conversely, while epithelial markers 
are repressed,  mesenchymal  markers are increased  during  EMT.  These  markers include 
N-cadherin, vimentin, and fibronectin 18. Folowing the transcriptional alterations of these 
adhesion  molecules,  protein  degradation and endocytosis aids in recycling epithelial 
adhesion molecules to promote progress through EMT 45. 
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1.3.3 EMT transcriptional targets 
Altered expression  of  EMT target genes, such as those involved in celular adhesion, 
often facilitate  migration and invasion 46–48.  Upon  detaching from the  basal epithelium, 
epithelial cels undergoing EMT may alter their extracelular environment by expressing 
matrix  metaloproteinases (MMPs) to  promote  directional  migration 49–51.  During 
migration, adhesion  molecules are  disproportionately redistributed  between the leading 
and trailing edge  of the cel,  which alows the cel to coordinate  directed  migration 
leading to tumor dissemination and metastasis 24,52. Beyond metastasis, EMT has recently 
been atributed to  more fundamental roles in cancer  biology including suppressing 
apoptosis and senescence 53.  The  EMT  has also  been implicated in immune evasion 54 
and  metabolic reprogramming 22,55 of cancer cels.  Together, the  data  discussed above 
suggest that the  EMT  program  promotes  many cancer cel  phenotypes leading to 
malignancy.  
 
1.4 The hexosamine biosynthetic pathway (HBP) 
 
1.4.1 Enzymatic steps of the HBP 
Since the 1950s, cancer has been notorious for its addiction to glucose and glutamine 7,56–
58. Upon depletion of these carbon sources in cancer cel culture media, celular growth is 
abrogated. Both glucose and glutamine are essential for the first commited step and rate-
limiting step of the HBP, the conversion of fructose-6-phosphate (Fru-6P) to 
glucosamine-6-phosphate. Approximately 2-5% of glucose (in adipocytes) is shunted 
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through the HBP 59. Demonstrating the importance of extracelular glucose 
concentrations on the HBP, glucose starvation reduces UDP-GlcNAc levels 60,61. 
Conversely, elevating extracelular glucose concentrations results in increased flux 
through the HBP 62. Figure 2A summarizes the four key enzymatic steps of the HBP:  
 
1)  Glutamine:fructose-6-phosphate transaminase (GFAT; GFPT)  utilizes  glutamine in a 
transamination reaction  which converts fructose-6-phosphate to  glucosamine-6P (GlcN-
6P); 
2)  GlcN-6P is converted to  N-acetylglucosamine-6-P (GlcNAc-6P)  by  Glucosamine-
phosphate N-acetyltransferase (GNPNAT; GNPNAT) which requires acetyl-CoA; 
3) Phosphoglucomutase (PGM; PGM) isomerizes GlcNAc-6P to N-acetylglucosamine-1-
phosphate (GlcNAc-1P);  
4)  UDP-N-acetylglucosamine  pyrophosphorylase (UAP1; UAP1) charges  GlcNAc-1P 





(Tapara, Frontiers in Oncology, 2016) 
 
 
Figure 1.2 The  hexosamine  biosynthetic  pathway (HBP) and  glycosylated  EMT 
targets 
 
(A) First, the rate limiting enzyme  of the  HBP,  glutamine:fructose-6-phosphate 
transaminase (GFAT),  uses  glutamine (Gln) as an amine  donor to convert  Fru-6P into 
glucosamine-6-P (GlcN-6P).  Second,  glucosamine-phosphate N-acetyltransferase 
(GNPNAT) N-acetylates  GlcN-6P in an acetyl-CoA-mediated reaction to form N-
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acetylglucosamine-6-P (GlcNAc-6P).  Third,  phosphoglucomutase (PGM) isomerizes 
GlcNAc-6P to the  highly active  GlcNAc-1P.  The final step is catalyzed  by  UDP–N-
acetylglucosamine  pyrophosphorylase (UAP1) and charges  GlcNAc-1P  with  UDP to 
form  uridine-5′-diphosphate-N-acetylglucosamine (UDP–GlcNAc). (B) UDP–GlcNAc 
(depicted as a  blue square) is essential for  N-glycosylation  processing and elongation. 
One critical  pivot  point includes the  branching  of complex N-glycans. Inhibiting this 
process  with a  bisecting  GlcNAc is associated  with tumor suppressive  phenotypes. In 
contrast, cancers  have aberant expression  of  glycosyltransferases responsible for 
branching and elongating complex N-glycans. (C) Many  of the  proteins commonly 
associated  with  promoting  EMT are  modified  by  glycans containing  GlcNAc and are 
found on the cel surface. Hyaluronan, a glycosaminoglycan, is also found extracelularly 
and is a polymer of glucuronic acid and N-acetylglucosamine. Many nuclear, cytoplasmic 
and  mitochondrial  proteins are  modified  by  monosaccharides  of O-linked N-
acetylglucosamine (O-GlcNAc), including many transcription factors, which appear to be 
stabilized  by  glycosylation63.  Numerous studies  have identified  various cancers  with 
elevated levels of pan-O-GlcNAcylation64. 
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1.4.2 Functions of the HBP 
Together, the four enzymes  of the  HBP  orchestrate the de  novo biosynthesis  of the 
charged  nucleotide sugar  UDP-GlcNAc from  glucose.  This  process can  be  manipulated 
by endogenous metabolites (i.e., glutamine)65 as wel as exogenous sugars (i.e., glucose, 
glucosamine, and  N-acetylglucosamine)66. Interestingly, this  pathway is  wel positioned 
to sense the four  macromolecules  of life, coordinating carbohydrate, amino acid, lipid, 
and  nucleotide  donors through  Fru-6P,  Gln, acetyl-CoA, and  uridine, respectively 67. 
Despite the limited flux through the HBP, celular UDP-GlcNAc levels can reach over 1 
mM  making it  one  of the  most abundant  high-energy celular compounds 68.  UDP-
GlcNAc is  utilized in the synthesis  of  numerous  glycoconjugates and is interconverted 
into  other  nucleotide sugars (e.g., UDP-GalNAc,  N-acetylmannosamine,  CMP-
Neuraminic acid),  which are incorporated into  glycoconjugates 69.  Together, the  glycan 
structures downstream of the HBP metabolite, UDP-GlcNAc, influence a wide range of 
functional targets highly relevant to cancer and EMT. 
 
1.4.3 Alterations of the HBP and global glycosylations in cancer 
Reinforcing the importance  of  UDP-GlcNAc incorporation, recent  data suggest the 
expression of multiple enzymes of the HBP and glycosyltransferases are altered in cancer, 
corelating  with  EMT, cancer  progression, and  metastasis. In a recent analysis  using 
unsupervised  hierarchical clustering  of  1,704  metabolic  genes and  nearly  1,000 cancer 
cel lines, Shaul and coleagues identified a “Mesenchymal Metabolic Signature” (MMS) 
22. In this  MMS,  both GFPT2 and UAP1,  key enzymes in the  HBP,  were found to  be 
essential for the  mesenchymal  phenotype 22,70. In  other studies,  metabolites  of the  HBP 
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(e.g., UDP-GlcNAc) levels  have  been reported to  be elevated in cancer cels and to 
promote cancer cel survival 60. 
 
Glycosyltransferases consistently elevated in  multiple cancers (e.g., stomach and 
pancreas cancer) include β-1,4-mannosyl-glycoprotein 4-β-N-
acetylglucosaminyltransferase (GNT3), α-1,6-mannosylglycoprotein  6-β-N-
acetylglucosaminyltransferase  A (GNT5), core  2 β-1,3-galactosyl-O-glycosyl-
glycoprotein β-1,6-N-acetylglucosaminyltransferase (Core  2  GNT;  GCNT1),  N-
acetylactosaminide β-1,6-N-acetylglucosaminyl-transferase-isoform  A (GCNT2), and 
UDP-N-acetylglucosamine-dolichyl-phosphate  N-acetylglucosaminephosphotransferase 
(GPT1), encoded  by the  genes MGAT3, MGAT5, GCNT1, and GCNT2, and DPAGT1, 
respectively 71. Notably, GNT5 is highly associated with breast, lung, and colon cancer 
metastasis 72–77, whereas GNT3  is associated with breast, skin, and colon cancer tumor 
suppression 78–80. GNT5 and GNT3 have antagonistic roles; GNT5 promotes complex N-
linked glycan branching, whereas GNT3 suppresses branching (Figure 2B). It is thought 
that changes in glucose flux through the HBP impacts the function of GNT3 and GNT5 66. 
The rate limiting enzyme that forms the  precursor for  N-glycosylation,  GPT1,  has also 
been shown to  drive  proliferation,  EMT, and cel  morphology 81.  As  discussed  below, 
flux through the HBP can alter the distribution paterns of glycosylation. To date, this has 
not  been specificaly studied in  EMT.  However, there are a  number  of  glycoconjugates 
afected by changes in UDP-GlcNAc availability or changes in their biosynthesis. These 
glycoconjugates and their impact on EMT are discussed below.  
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1.5 External GlcNAc-containing glycoconjugates observed 
during EMT 
 
1.5.1 GNT3 and GNT5 mediated N-glycosylation in cancer 
Accumulating evidence strongly suggests that changes in  protein  glycosylation impact 
numerous cancers including melanoma 82, pancreas 83,84, colon 85, ovarian and breast 86, 
brain and lung 87, liver 88, and  prostate 89 cancers.  Generaly, alterations in  N-glycan 
structure  profoundly afect celular adhesion and epithelial  morphology in vitro 90. 
Figures  2B  and  2C show that  many  glycoproteins  utilizing  UDP-GlcNAc in their 
biosynthesis occur on key EMT adhesion molecules (e.g., E- and N-cadherin). E-cadherin 
has four  putative  N-linked  glycosylation sites 91,  which are  modified  by complex  N-
linked glycans. The number of “antennae” on these glycans is regulated by the competing 
activities  of  GNT3 (MGAT3) and  GNT5 (MGAT5).   The introduction  of a  bisecting 
GlcNAc by GNT3 (Figure  2B) reduces the number of antennae and thus complexity of 
the N-linked glycan. 
 
1.5.2 Glycosylation of E-cadherin 
Epigenetic regulation  of the  gene encoding  GNT3, MGAT3, stabilizes  E-cadherin and 
inhibits  EMT 92. In contrast, elevated activity  or expression  of  GNT5 results in  more 
complex  N-glycans  which impairs  E-cadherin localization and celular aggregation in 
mice 93.  Additional studies in  mice  have revealed that Mgat5 knockdown leads to a 
reduction  of  N-glycosylated  E-cadherin,  which increases  E-cadherin cis-dimerization, 
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catenin recruitment, and cel  membrane localization 94,95. Importantly, aberantly  N-
glycosylated  E-cadherin is found in  gastric cancer  patients and correlates  with  poor 
patient survival 94. 
 
1.5.3 Glycosylation of N-cadherin 
Mesenchymal N-cadherin is also modified by N-linked glycans, and the modification of 
these  glycans  with  GlcNAc  by  GNT5  promotes cel  migration,  MAPK signaling, and 
reduced adhesion 96,97.  Furthermore,  N-cadherin  N-glycans atract  Galectin-3, forming 
highly  organized lipid rafts  on the cel surface,  which stabilizes the  galectin latice and 
enhances cancer cel mobility 98. This galectin latice structure also recruits several major 
signaling receptors such as epidermal growth factor (EGF) receptor (EGFR) and TGF-β 
to promote oncogenic signaling 99,100. 
 
1.5.4 Glycosylation of integrins 
Integrins are  heterodimeric  glycoproteins responsible for cel-cel and cel-extracelular 
matrix interactions 101. The α5β1 integrin serves as the receptor for fibronectin and their 
interaction is critical for celular  migration in  development 102–104.  While  both integrin 
and fibronectin are N-glycosylated, the activity of GNT3 is associated with shorter less 
complex  N-glycans  which is thought to result in reduced integrin-mediated  EMT 
signaling 105,106.  Additionaly,  without  N-linked  glycans, integrins show significantly 




1.5.5 Glycosylation of RTKs 
Receptor tyrosine  kinases (RTKs) are  vital to the transduction  of external stimuli into 
internal signals for induction of EMT in many cancers (e.g., carcinomas). Interestingly, 
RTKs involved in  growth and  proliferation (e.g., EGFR)  have approximately five-fold 
more  N-glycosylation sites than receptors,  which are involved  with  organogenesis, 
diferentiation,  or cel cycle arest 108.  The  HBP  has  been shown to  drive changes in 
EGFR N-glycosylation; feeding both GNT5 wildtype and GNT5 nul tumor cels with N-
acetylglucosamine elevated  UDP-GlcNAc levels and the  number  of terminal  GlcNAc 
residues  on cel surface  proteins.  Analysis  of the  N-linked  glycans  demonstrated 
increased flux through the HBP results in increased triantennary structures in GNT5 nul 
cels (2 fold) and a smaler increase in both tri- and tetra-antennary N-glycans in GNT5 
wild-type cels.  Functionaly, increased flux through the  HBP altered  EGFR  plasma 
membrane retention, active conformation,  EGF ligand  binding, and inhibition  of 
endocytosis  mediated  degradation 109,110.  N-glycosylated  EGFR recruits  N-glycosylated 
TGF-βR to the galectin latice thereby promoting TGF-β and SMAD autocrine signaling. 
TGF-βR with highly branched glycans, a result of increased GNT5 activity, localizes to 
the plasma membrane, binds galectin-3, inhibits receptor endocytosis, enhances TGF-βR 
heterodimerization, increases tumor  metastasis, and  promotes  EMT-mediated cel 
migration 100,111. TGF-β itself upregulates GCNT1, a critical GlcNAc branching enzyme, 
producing similar efects in prostate, colorectal, pancreatic, testicular, and breast cancers 
112. 
 
1.5.6 Glycosylation of the WNT, NOTCH, and HH pathways 
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The  WNT,  NOTCH, and  Hedgehog (HH)  pathways are also critical for  EMT and are 
modified  by  glycans that  utilize  GlcNAc for  modulation  of  pathway activity.  Al  19 
known WNT ligands contain at least one N-linked glycosylation site and these sites are 
critical for ligand  maturation, lipid  processing, secretion, and β-catenin signal 
transduction 113,114.  WNT also regulates transcription  of DPAGT1 to  promote  EMT 
through E-cadherin glycosylation 81. 
 
The  Notch signaling  pathway regulates cel  proliferation, survival, and  diferentiation 
while  glycosylation  of components in this  pathway are associated  with  poor  prognosis 
and  metastasis in  numerous cancers 115,116.  Over two  decades  of research  demonstrates 
the extracelular  domain  of  Notch receptor is  glycosylated  with  N-linked 117,  O-fucose 
117,118, O-GlcNAc 119, and O-glucose 117,120 glycans. Extension of O-fucose with GlcNAc 
(catalyzed  by O-fucosylpeptide  3-beta-N-acetylglucosaminyltransferase [Fringe in 
Drosophila]) alters Notch ligand-receptor specificity. In Drosophila, extended O-fucose 
glycans are associated  with increase sensitization  of  Notch to the  Delta ligands and 
reduced sensitivity to the Serate/Jagged ligands 116. Litle is known about the impact of 
altered  HBP flux  on the  Notch receptor, although  one might  postulate that changes in 
UDP-GlcNAc levels  may alter  Notch  glycosylation and thus signaling  downstream  of 
this receptor. In the  Sonic  HH  pathway, the  G  protein-couple receptor (GPCR), 
Smoothened (SMO), is activated to promote cel proliferation and migration 121. Recently, 
critical  N-glycans  on  SMO  were found to abrogate  HH induced cel  migration  due to 




1.5.7 Hyaluronan in cancer 
Beyond the suite of GlcNAc-modified adhesion molecules and receptors, hyaluronic acid 
(hyaluronan  or  HA) is an  oligomer found  ubiquitously in the extracelular space 
particularly of connective, epithelial, and neural tissues 123. Human HA is a massive (0.5–
2  MDa)  unbranched  glycosaminoglycan composed  of the repeating  disaccharide 
consisting of GlcNAc and glucuronic Acid (GlcNAcβ1-4GlcAβ1-3) 124. It is synthesized 
by HA synthase (HAS) and is extruded through the plasma membrane as it is synthesized. 
Recent reports suggest hyaluronan synthesis and catabolism is controled UDP-GlcNAc 
concentrations,  with  hyaluronan serving as a sink for excess  UDP-GlcNAc 125.  Recent 
studies  have  demonstrated that  modulating levels  of  UDP-GlcNAc and  glucuronic acid 
alter the localization of the HAS enzymes 126. Low levels of UDP-GlcNAc are associated 
with an inhibition  of  HA synthesis,  whereas elevated levels  of  UDP-GlcNAc are 
associated with HA synthesis and melanoma progression 126. Consistent with these data, 
several studies  have  demonstrated  patients  with  higher-extracelular  HA  or  HAS 
expression  have a  worse  prognosis and survival  with  more aggressive and  metastatic 
cancers including  breast 127–129,  prostate 130,131, lung 132,133,  pancreatic 134, colorectal 135, 
and ovarian 136 cancers. With respect to EMT, high levels of HA are suficient to induce 
the EMT in kidney and mammary epithelial cels 137. Taken together, HA synthesis is in 
part  driven  by the  HBP,  has  been associated  with  EMT and is found at  high levels in 
many cancers. 
 
1.6 Nuclear, cytoplasmic, and mitochondrial glycosylations 
observed during EMT 
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1.6.1 O-GlcNAcylation overview 
UDP-GlcNAc can also be utilized for the synthesis of O-Linked β-N-acetylglucosamine 
(O-GlcNAc), an essential PTM of metazoans 138. O-GlcNAc is found on more than 3,000 
cytoplasmic,  nuclear, and  mitochondrial  proteins 67.  O-GlcNAcylation is thought to 
regulate protein function in a manner analogous to phosphorylation. O-GlcNAc has been 
demonstrated to regulate celular processes such as epigenetics, transcription, translation, 
protein degradation, metabolism, ribosomal bioenergentics and cytokinesis 139. 
 
Unlike  N-glycans, the  O-GlcNAc  modification (or  O-GlcNAcylation) consists  of a 
monosaccharide of GlcNAc covalently atached to serine and threonine residues through 
an  O-glycosidic  bond 138.  Where  N-linked  glycan synthesis and  processing is regulated 
by upwards of 18 enzymes (depending on the structure formed), the dynamic cycling of 
O-GlcNAc  on  proteins is regulated  by just two enzymes: the  O-GlcNAc transferase 
(OGT) and the O-GlcNAcase (OGA), which add and remove O-GlcNAc, respectively 140. 
OGT activity and substrate specificity is regulated  by changes in  UDP-GlcNAc 
concentrations and this has led many to suggest that OGT may regulate cel function in a 
manner dependent on extracelular glucose concentrations 140.  
 
1.6.2 O-GlcNAcylation in cancer 
Cancer cels which are dependent on glucose and glutamine have been demonstrated to 
have  high  UDP-GlcNAc levels (discussed above),  high  O-GlcNAc levels, and in some 
cases increased expression  of  OGT 140. In sum, elevated  protein  O-GlcNAcylation and 
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OGT expression  have  been reported in  numerous  malignancies including  breast 
16,63,141,142,64,  prostate 143–145, lung 146,  pancreas 147, liver 148, and colon 146,149,150 cancers. 
Importantly, levels  of  O-GlcNAc,  OGT, and  OGA  have corelated  with aggressiveness 
(e.g. Gleason score for prostate cancer) in a number of patient tumor samples including 
prostate 144, breast 64, endometrial 151, and bladder 152 cancers.  
 
1.6.3 O-GlcNAcylation of TFs in cancer 
One important class  of  proteins  heavily  O-GlcNAcylated are  TFs (Figure  2C).  Early 
analyses suggested that over 25% of known O-GlcNAcylated proteins were TFs 14. For 
many  of these  TFs,  O-GlcNAcylation serves as a  direct  or indirect competitor  of  key 
phosphorylation sites 140.  Particularly relevant to  EMT is the  O-GlcNAcylation and 
regulation of SNAI1. Upon serial phosphorylation by CK1 and glycogen synthase kinase 
(GSK)-3β,  SNAI1 is  primed for  nuclear export, β-TrCP  ubiquitination, and subsequent 
proteosomal  degradation 153,154. Interestingly,  SNAI1 is  O-GlcNAcylated in 
hyperglycemic conditions  preventing  GSK-3β  phosphorylation  which results in  SNAI1 
stabilization 155.  O-GlcNAcylated  SNAI1 is associated  with enhanced  EMT and 
migration,  which is linked to a repression  of  E-cadherin.  Whether  other  EMT-inducing 
TFs are similarly regulated by O-GlcNAcylation is yet to be determined. Beyond SNAI1, 
O-GlcNAcylation  occurs  on other transcription factors  generaly relevant to cancer 
including c-Myc 156,157, β-catenin 158,  C/EBPβ 159,  p53 160, and  FoxO1 161,  NFkB 162,163. 
Thus, while more experimentation is needed to demonstrate causality between EMT and 




1.6.4 O-GlcNAcylation and the cel cycle 
Previous studies from  our lab and  others  have elucidated the role  of the  EMT  TF, 
TWIST1, in suppression  of  oncogene-induced senescence (OIS) 20,21,164.  While  normal 
cels respond to  oncogene activation  with  p53-p19ARF,  p16-Rb and  Atf4-p27KIP-
dependent  OIS 165,166, suppression  of these  pathways through  EMT  TFs  provide an 
alternative route for cancer to  maintain cel cycle  progression and  proceed along a 
tumorigenic  path.  Due to the  metabolic regulation  of the cel cycle, it is  not surprising 
many  of these  proteins  orchestrating celular  division are also  O-GlcNAcylated. 
Knockdown of OGT results in elevated expression of p27Kip 63, a reduction of cyclin D1 
and B1, and diminished PI3K/AKT signaling 167, suggesting that OGT/O-GlcNAc plays 
key roles  during cel cycle  progression.  Furthermore,  OGT is thought to control 
cytokinesis as it is localized to the mitotic spindle where it interacts with Polo-like kinase. 
Disrupting O-GlcNAcylation results in defects in cytokinesis and multinucleated cels 168. 
Overal,  global  O-GlcNAc levels  have  numerous efects  on the cel cycle, indicative  of 
yet another link to advancing the neoplastic phenotype. 
 
1.6.5 Bridging the gap 
The  data  discussed  here  highlight alterations in intracelular and extracelular 
glycoconjugates that impact  diferent  EMT tumorigenic  pathways and associated 
proteins/biomolecules.  With recent controversies  of  EMT transcription  programs 
continuing to  unfold 169,170, it is likely that role  of  EMT  may extend  beyond cancer 
development and metastasis, including cancer treatment resistance. Thus, understanding 
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how changes in  metabolic  pathways  observed in cancer (e.g., the  HBP) impact the 
distribution and composition  of  glycoconjugates  may  provide  deeper insights into 
mechanisms of cancer biology. While most of the research discussed here demonstrates 
the  potential for  glycoconjugates to regulate  EMT, it  may  be interesting to see in the 
future how EMT reciprocaly promotes metabolic reprogramming and the HBP. 
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Chapter 2: Investigating the EMT-HBP axis in lung cancer 
 
2.1 Background on EMT and OIS in mutant KRAS-driven lung 
cancer 
Non-Smal Cel Lung Cancer (NSCLC) mortality remains high with the most frequently 
observed  driver  mutation  occuring in the smal  GTPase, KRAS171.  Recent evidence 
suggest aberant KRAS drives glycolytic flux in lung cancer172,173, potentialy impacting 
aberant  protein  glycosylation.  One contributor and  proposed target  of KRAS driven 
cancers is a developmentaly conserved epithelial plasticity program caled the epithelial-
mesenchymal transition (EMT)174. Recently, the EMT has been corelated with aberant 
glycosylation to  promote  neoplastic  phenotypes175.  Despite its  prevalence and three 
decades  of research, the  KRAS  oncoprotein remains  dificult to target 
pharmacologicaly176.  A beter  understanding  of  metabolic susceptibilities  may reveal 
innovative targets. 
 
Here we show in novel autochthonous mouse models that EMT accelerates KrasG12D lung 
tumorigenesis by driving expression of hexosamine biosynthetic pathway (HBP) genes to 
elevate the O-linked β-N-acetylglucosamine post-translational modification (PTM) on 
intracelular  proteins (O-GlcNAcylation)138.  O-GlcNAcylation  promoted suppression  of 
KrasG12D oncogene-induced senescence (OIS) and accelerated lung tumorigenesis. 
Genetic and  pharmacological inhibition  of the  HBP revealed this  metabolic  pathway is 
required for  EMT-mediated suppression  of  OIS.  We show that the  O-GlcNAcylated 




Our results demonstrate for the first time that O-GlcNAcylation is suficient and required 
to accelerate KrasG12D lung tumorigenesis in vivo, which is reinforced by EMT programs. 
These  data  hold  potential as an alternative “metabolic strategy” to target  mutant KRAS 
driven lung cancers  by activating latent senescence  programs.  Furthermore,  our  work 
provides fundamental  new insights into a  unique sugar  post-translational  modification 
(PTM) that is required for KrasG12D-driven lung tumorigenesis. 
 
In the presence of an oncogenic driver, normal primary cels initiate an intrinsic failsafe 
mechanism,  OIS, in response to oncogenic celular stress, characterized  by  permanent 
cel cycle arest, cytoplasm enlargement, and the senescence-associated secretory 
phenotype (SASP)177,178. To progress towards ful-blown malignancy, these  pre-
malignant cels  must initiate programs to suppress OIS. We and  others have previously 
shown the EMT transcription factors (TFs) – commonly associated  with cancer 
aggressiveness, metastasis, and stemness – suppress OIS and accelerate KrasG1D–induced 
tumorigenesis20,21,179. This novel  EMT function is particularly impactful given recent 
discoveries suggesting  diverse roles  of the  EMT in cancer beyond metastasis (e.g. 
chemoresistance)169,170. Thus,  EMT programs hold  promise for identifying alternative 
pathways to target mutant KRAS. 
 
2.2 The  development  of  novel mutant KRAS-driven  EMT  mouse 
models 
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Two  wel-characterized EMT TFs are SNAI1 and  TWIST1,  which are  both critical in 
development, aberantly expressed in numerous cancers, and corelate with poor patient 
outcomes24,174. We  generated  novel lung specific inducible  mouse models  of EMT co-
expressing mutant KrasG12D and SNAI1 (CRS) or TWIST120 (CRT) and compared them to 
mice expressing KrasG12D alone (CR) (Fig.  2.1a, 2.5a,  b). Consistent  with  our  previous 
work  on  EMT20, cone-beam computed tomography (CBCT) scans (Fig.  2.1b) revealed 
EMT expressing  CRS and  CRT  mice developed tumors twice as quickly (median  = 16 
weeks) as CR mice  overexpressing KrasG12D alone (median  =  32 weeks) and have 
significantly more tumors (Fig. 2.1c and Fig. 2.5c, d). Furthermore, while CR mice tend 
to  develop adenomas, the  EMT CRS and  CRT mice  developed adenocarcinomas (Fig. 
2.1d), which were dependent on the co-expression of KrasG12D and an EMT TF for tumor 
maintenance (Fig. 2.5e). The  CRS and  CRT tumors also showed high proliferation, 
activated MAPK signaling, modestly decreased apoptosis, and low senescence relative to 
CR tumors (Figs. 2.1e, f, 2.5f, g, and Ref. 20). To demonstrate EMT suppression of OIS, 
we  generated SNAI1 and  Twist120 expressing  mouse embryonic fibroblast (MEF) cel 
lines and found EMT  TF expression suppressed  mutant RAS-induced  OIS as shown by 
activated proliferation and reduced senescence-associated β-galactosidase (SA-βgal) 
staining (Fig.  2.6). Overal, EMT TFs suppressed OIS, accelerated lung tumorigenesis, 
and promoted lung tumor  progression towards aggressive adenocarcinoma in KrasG12D-
driven lung cels. 
 
2.3 Identification of EMT associated metabolic gene expression 
To identify  mechanisms  of EMT-mediated suppression  of  OIS,  we  used  mRNA 
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microaray analysis to identify diferentialy expressed genes  between  CR vs CRS and 
CR vs CRT lung tumors. Gene Set Enrichment Analysis (GSEA) revealed a number of 
gene sets related to the EMT, senescence, and mutant KRAS-driven lung cancer (Fig. 2.7). 
Interestingly,  using the  PANTHER (Protein  ANnotation through  Evolutionary 
Relationship) Gene Ontology (GO) classification system, we identified 1/3 and 1/5 of the 
diferentialy expressed genes were involved in “metabolic biological processes”, in CR 
vs CRS and CR vs CRT models, respectively (Fig. 2.1g, h). Seahorse metabolic analyses 
indicated that EMT TF expressing NSCLC cels,  A549 and  PC9, exhibited elevated 
glucose utilization (Fig. 2.8). As we were interested in mechanisms of glycolytic flux, we 
then found the EMT mouse lung tumors corelated with increased expression of critical 
genes in the HBP, a  versatile energy-sensing pathway  downstream  of  glycolysis. 
Specificaly, EMT TFs corelated with elevated expression  of the rate limiting step 
(GFPT2) and final enzymatic step (UAP1) of the HBP as confirmed  by  qPCR and 
Western  blot in  both EMT mouse  models (Fig.  2.1i-k) and in patient lung 
adenocarcinoma data from cBIO and The Cancer Genome Atlas (TCGA) (Fig. 2.1l and 
Fig. 2.8a). 
 
In addition, both the transcriptomic profile of mesenchymal stem cels (Fig. 9b, c) and a 
recently discovered cancer “Mesenchymal  Metabolic  Signature” (MMS)22 showed 
upregulation  of  both GFPT2 and UAP1. Interestingly, GFPT2 was the top metabolism 
gene significantly overexpressed in tumorigenic KRASG12D-driven human lung epithelial 
cels180. We found GFPT1 and UAP1 were overexpressed in 20 NSCLC gene expression 
datasets accessed  on  ONCOMINE (Fig.  2.9d).  To  verify this  EMT-HBP axis,  we 
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overexpressed SNAI1 and TWIST1 in human mutant KRAS-driven NSCLC cel lines and 
found that HBP genes were similarly overexpressed (Fig. 2.1m, n). Additional inducible, 
knockdown and overexpression models of EMT including NSCLC cels, HeLa cels, non-
malignant cels, and  CRS  mice  without  DOX induced SNAI1/KrasG12D showed direct 
corelation  with HBP  genes (Fig. 2.9e-i). Together, these  data suggested a  novel  EMT-
HBP in NSCLC cels, patient samples, and our in vivo EMT-accelerated KrasG12D lung 
tumorigenesis mouse models. 
 
2.4 The HBP is required for SNAI1-mediated suppression of OIS 
To determine the requirement of the HBP in senescence, we made use of the non-cancer 
human bronchial epithelial cel line (HBEC3-KT)181 that activated an OIS transcriptional 
phenotype upon HRASG12V transduction (Fig. 2.2a-c). Inhibition of the HBP (Fig. 2.2d) in 
HBEC3-KTs geneticaly and pharmacologicaly induced  markers  of senescence and 
decreased cel counts (Fig.  2.2e and  2.10a-e). As the glutamine antagonist 6-Diazo-5-
oxo-L-norleucine (DON) is not a specific inhibitor of GFPT2, we also demonstrated that 
senescence was specific to the  HBP with a metabolite rescue experiment: addition  of 
downstream metabolites of the HBP rescued 50 µM DON induced-senescence (Fig. 2.2f 
and Fig. 2.10f, g), suggesting the HBP is a critical pathway controling senescence.  
 
We also found SNAI1 could suppress HRASG12V-mediated OIS in HBEC3-KT cels (Fig. 
2.2g,  h, first two  bars), in alignment  with  our  previous  work  with TWIST1 expressing 
MEFs20.  Genetic (Fig.  2.2g and Fig.  2.10h) and  pharmacological (Fig.  2.2h and Fig. 
2.10i) inhibition  of the  HBP abrogated the ability  of  EMT  TF expression to suppress 
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HRASG12V-mediated OIS in our SNAI1 overexpressing HBEC-3KT model. 
 
2.5 A SNAI1-inducible, mutant KRAS-expressing conditional  mouse 
model 
To  determine if the  EMT TF expression directly impacts the  HBP and  OIS in vivo,  we 
crossed our inducible SNAI1 expressing mouse line (CS) with the conditionally activated 
Lox-Stop-Lox-KrasG12D (LSL)182 to generate a novel triple transgenic CS-LSL mouse line 
(Fig. 2.10j and Ref. 20). 
 
In support of our findings in the CRS mouse model (Fig. 2.2), CS-LSL mice generated 
more rapidly growing, less senescent, and more aggressive tumors compared to LSL mice 
(Fig. 2.2i). With this model, we were able to inactivate expression of SNAI1 alone while 
maintaining expression  of KrasG12D and found that inactivation of  SNAI1  promoted 
tumor stasis and elevated levels of p53 (Fig. 2.2j-m). Furthermore, without the EMT TF 
SNAI1, mRNA expression of the HBP genes diminished (Fig 2m). Thus, EMT-mediated 
suppression  of  mutant RAS-induced  OIS required the  HBP in vitro and  SNAI1  directly 
modulated the HBP in vivo. 
 
2.6 Targeting the HBP in NSCLC affects cancer growth 
Genetic knockdown of GFPT2 and UAP1 in NSCLC cels revealed increased markers of 
senescence (Fig. 2.3a, b and Fig. 2.11a, b). Pharmacological inhibition of the HBP with 
low concentrations  of  DON (<10 µM) in  NSCLC cel lines showed  decreased cel 
viability,  decreased clonogenicity, increased senescence  morphology, and elevated 
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molecular markers  of senescence and apoptosis, while  normal HBEC3-KT cels were 
seemingly  unafected (Fig.  2.3c-g and Fig.  2.11c-g). To assess the eficacy  of targeting 
NSCLC cels in vivo, H358 (Fig. 2.3h-j and Supplementary 12a-d) and A549 (Fig. 2.12e-
h) cels were injected into the flanks of athymic nude mice. Mice treated with DON (20 
mg/kg/week) resulted in smaler tumors, reduced tumor  growth, reduced gross tumor 
weight, and increased  markers  of senescence over five  weeks without significantly 
impacting  body  weight (Fig.  2.12d). DON treatment also inhibited autochthonous lung 
tumorigenesis in the CS-LSL and CT-LSL mice tumors without impacting body weight 
(Fig.  2.3k-m and Fig.  2.12i-k). Therefore, targeting the  HBP in lung cancer inhibited 
early lung tumorigenesis and had therapeutic efects on established tumors that resulted 
in senescence and/or cel death. 
 
2.7 O-GlcNAcylation is upregulated in response to EMT 
The HBP produces the nucleotide sugar UDP-GlcNAc which can be utilized in multiple 
pathways, including both N-linked and O-linked protein glycosylations (Fig. 2.4a), which 
regulate protein stability and activity63,70,175. N-linked glycosylation of proteins occurs in 
the  ER and  Golgi and the  branching  of  N-glycans is influenced  by flux through the 
HBP183. Interestingly, the O-GlcNAc  PTM (O-GlcNAcylation) has previously been 
shown to stabilize  SNAI1 in the  nucleus155.  O-GlcNAcylation is a single sugar 
modification found  on  proteins in the  nucleus, cytoplasm, and  mitochondria139. The  O-
GlcNAc  modification138,139 is added and removed  by just two enzymes,  O-GlcNAc 
Transferase (OGT) and  O-GlcNAcase (OGA), respectively (Fig.  2.4a).  In  our  models 
overexpressing  EMT  TFs,  we found that the  HBP, OGT, and  O-GlcNAcylation  were 
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elevated in both human (Fig. 2.4b, Fig. 2.13a, c and 2.16a) and mouse (Fig. 2.4f-k, Fig. 
2.13b and 2.10) NSCLC cels. Analysis with ConA did not reveal a noticeable change in 
the degree of N-linked glycosylation (Fig. 2.4b and Fig. 2.14a). 
 
To  determine  which type  of glycosylation afected senescence,  we  used  genetic and 
pharmacologic inhibition of N-linked glycosylation and the O-GlcNAc glycosylation. We 
found reduction of O-GlcNAcylation in HBEC3-KT cels, via genetic overexpression of 
OGA (Fig.  2.4c) and pharmacological inhibition  with  OGT inhibitor  TT04 (Fig. 2.4d), 
promoted senescence while inhibition of N-glycosylation with tunicamycin (TUNI) had 
no efect on senescence (Fig. 2.15). Reducing O-GlcNAcylation in NSCLC cels in vitro 
with the OGT inhibitor  TT04 increased SA-βGal positive staining and  promoted 
senescent celular  morphology in NSCLC cels (Fig.  2.4e and Fig.  2.16b, c). DON 
treatment also reduced  global  O-GlcNAcylation in vitro and in vivo (Fig. 2.16d, e). 
Genetic  knockdown  of  OGT in  A549 cels reduced NSCLC clonogenicity and 
endogenous levels of SNAI1 (Fig. 2.16f, g).  Genetic ablation of OGT reduced celular 
number upon conditional OGT knockout in MEFs over 5 days (Fig. 2.16h). These data 
indicate that EMT and the sugar PTM O-GlcNAcylation promoted each other in a feed-
forward loop to regulate senescence. 
 
2.8 Connecting O-GlcNAcylation and mutant KRAS-mediated OIS 
We next wanted to know the importance of O-GlcNAcyaltion for KrasG12D–induced lung 
tumorigenesis  by using established and  novel autochthonous  mouse  models.  O-
GlcNAcylation  was suficient to significantly accelerate KrasG12D–induced lung 
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tumorigenesis as shown  by  pharmacological elevation  of  O-GlcNAcylation  with the 
OGA inhibitor thiamet-G (TMG) in the LSL model (median = 5 weeks; Fig. 2.4l-n, q). 
Requirement of O-GlcNAcylation was assessed by crossing the LSL mouse line with cre-
conditional OGTfl/fl mouse line184,  generating  LSL-OGTfl/fl mice that simultaneously 
express KrasG12D while  knocking  out OGT specificaly in the lung epithelial cels upon 
intranasal administration  of  Adeno-CMV-Cre (AdCre) virus (Fig.  2.4o,  p). Male  LSL-
OGTfl/Y mice demonstrated O-GlcNAcylation  was required for KrasG12D-induced lung 
tumorigenesis as demonstrated by a significant delay in lung tumor development (medial 
= 15 weeks; Fig. 2.4q). Overal, data from these autochthonous mouse models revealed 
O-GlcNAcylation was necessary and suficient for KrasG12D-induced lung tumorigenesis. 
 
Having established that the  EMT-HBP axis required O-GlcNAcylation to suppress 
senescence and accelerate KrasG12D-induced lung tumorigenesis, we then focused on O-
GlcNAcylated candidates that  have  been shown to be critical for tumorigenesis.  One 
promising target was the oncoprotein c-Myc based on multiple studies that KrasG12D and 
MYC oncogenes can have colaborative efects during tumorigenesis in vivo185–187 and c-
Myc itself is stabilized  by  O-GlcNAcylation157. We found MYC gene sets  were over-
represented  by GSEA in our EMT KrasG12D -driven lung cancer mouse  models (Fig. 
2.16i).  We found  pharmacological inhibition  of O-GlcNAcylation with TT04  or  DON 
(Fig. 2.16c-e, j)  or genetic  knockdown (Fig. 2.16g) resulted in a reduction  of c-Myc in 
human and mouse NSCLC cels in vitro and in vivo. Similarly, overexpression of EMT 
TFs in  human and  mouse NSCLC cels resulted in increased c-Myc levels in vitro 
(Supplementary  12a, k) and in vivo (Fig.  2.4h, i, r, s, Fig.  2.14c, e and  16l). Taken 
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together,  our  data suggested the  EMT-HBP axis suppressed  OIS through stabilizing 
oncogenes such as c-Myc.  
 
Our  work revealed that  EMT promotes increased  glucose flux through the  HBP to 
increase levels of O-GlcNAcylated proteins in incipient and established lung cancer cels 
as wel as autochthonous lung cancer models. This metabolic sugar pathway and protein 
O-GlcNAcylation are required to suppress mutant KrasG12D-induced  OIS and promote 
KrasG12D-induced lung tumorigenesis. Targeting the  HBP abrogates EMT-mediated 
suppression of OIS in normal HBEC3-KTs in vitro as wel as multiple mouse models of 
lung cancer in vivo. The benefit of these findings are highlighted by recent proposals for 
senescence programs as an alternative strategy for cancer therapy, especialy  with the 
clearance of senescent cels by the immune system178,188. Together, our data demonstrate 
O-GlcNAcylation is a product of EMT-driven metabolic reprogramming that contributes 
to KrasG12D-induced lung tumorigenesis and tumor progression. Modulation of the HBP 
and specific  glycosylations  may impact cel  death and senescence,  providing a novel 
targetable EMT-HBP axis for KRAS driven NSCLC. 
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Figure 2.1 The EMT drives the HBP in KRAS mutant lung cancer cels 
a,  Breeding schematic  of  doxycycline (DOX) inducible  Club  Cel  Specific  Promoter 
(CCSP; C)-driven lung-specific KrasG12D mouse line (CR) crossed with either SNAI1-6SA 
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(CRS) or Twist1 (CRT) mice with a bidirectional promoter also expressing a luc reporter. 
b, Bioluminescence imaging (BLI) and computerized tomography (CBCT) scans of mice 
(H - heart; S - spine) upon addition of DOX to drinking water. c, Kaplan-Meier curve for 
tumor free survival of EMT TF-KrasG12D mice (median = 16 weeks post-DOX) compared 
to KrasG12D alone (median = 31 weeks post DOX) (n≥26 mice per genotype; P<0.0001 by 
log-rank test). d,  Hematoxylin and eosin (H&E) staining  of representative  mouse lung 
tumors in b at  ~40  weeks. e, f, immunohistochemistry (IHC)  of  Ki67 and  p16 in  CR, 
CRS, and CRT tumors with quantification (n≥3 mice per genotype). g, h, Enrichment for 
genes of “Metabolic Process” Gene Ontology of diferentialy expressed genes between 
EMT and non-EMT driven mouse tumors. i-k, qPCR (i) and Western blot (j, k) for HBP 
genes, Gftp2 and Uap1, and coresponding  gene  products in  EMT/KrasG12D CRS/CRT 
tumors compared to KrasG12D alone  CR lung tumors (n≥5  mice  per  genotype). l, 
Corelation of  multiple  genes, including GFPT2 and UAP1, in lung adenocarcinoma 
patient samples from cBIO database (calculated by Pearson and Spearman corelations). 
m, n, HBP gene expression in NSCLC cel lines stably infected with SNAI1 or TWIST1. 
Unless stated, error bars, mean ± standard deviation (s.d.) P values were derived from an 







Figure 2.2 The HBP is required for EMT-mediated suppression of OIS 
a-c, Human  Bronchial  Epithelial  Cels (HBEC-3KT;  HBEC) cels infected  with 
HRASG12D were imaged (phase contrast, GFP fluorescence microscopy, and senescence-
associated β-galactosidase (SA-βGal) staining) (a),  quantified for  SA-βGal (b), and 
analyzed for  mRNA expression  of senescence  markers (c). d, The  HBP  metabolites, 
enzymatic steps, and the inhibitors  of the  pathway. e, qPCR  of senescence  gene 
expression in  HBECs treated  with  high concentration (50 µM)  of  6-diazo-5-oxo-L-
norleucine (DON) for  48  hours. f, SA-βGal  quantification  of  HBECs for  metabolite 
rescue with glucosamine (GlcN) (P<0.001 by One-way ANOVA with Dunnet’s multiple 
comparison test). g, h, SNAI1-mediated OIS suppression was assessed with genetic (g) or 
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pharmacological (h) inhibition  of the  HBP (P<0.001  by  One-way  ANOVA  with 
Dunnet’s multiple comparison test). i, Representative CBCT scan, H&E, and SA-βGal of 
lox-stop-lox-KrasG12D (LSL) and  LSL crossed  with  EMT  TF  SNAI1 (CS-LSL). j-m, 
Representative  BLI (j),  CBCT (k),  H&E (l), and  qPCR (m)  of  CS-LSL  mice  with and 
without inactivation  of  SNAI1 expression  by  withdrawing  DOX from  mouse  drinking 
water, while maintain expression of KrasG12D expression. Unless stated, eror bars, mean 








Figure 2.3 Targeting the  HBP in  mutant KRAS lung cancer cels 
results in senescence 
a-b, qPCR for senescence genes in NSCLC cel lines folowing 48 hours of GFPT2 and 
UAP1 siRNA knockdown. c-g,  Proliferative capacity (c), senescence  morphology (d), 
senescence gene expression by mRNA (e), senescence protein marker expression (f), and 
SA-βGal staining (g) of NSCLC cel lines treated with ≤10 µM DON for 48 hours. h-j, 
Tumor appearance (h),  quantified tumor  volume (n≥10 tumors  per arm; P<0.0001  by 
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two-way  ANOVA folowed  by  Holm-Sidak’s  multiple comparisons test) (i), and  qPCR 
for senescence gene expression (j) of H358 NSCLC cel line xenograft in athymic nude 
mice treated  with  20  mg/kg/week  DON  versus control for  5  weeks. k-m,  Contingency 
table (P<0.05 by Fisher’s exact test) (k), CBCT scan (l), and H&E (m) of CS-LSL mice 
treated  with  DON  20  mg/kg  BID.  Unless stated, eror  bars,  mean  ± s.d. P values  were 








Figure 2.4 O-GlcNAcylation is required to stabilize SNAI1 and c-Myc 
to suppress senescence 
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a,  Schematic  of  UDP-GlcNAc incorporation into  N-linked and  O-linked  glycosylation 
with inhibitors (red). b,  Efects  on  N-glycosylation (Concanavalin  A) and  O-
GlcNAcylation (CTD110.6)  with  48  hour  SNAI1 transient expression in  A549 cels. c, 
SA-βGal staining of  48  hour  genetic ablation  of  O-GlcNAcylation  via transducing 
HBECs  with  OGA  overexpression  viral construct. d,  SA-βGal staining folowing 
pharmacological inhibition  of  N-glycosylation (0.5 µg/mL tunicamycin;  TUNI) 
compared to  OGT inhibition (0.5 µM  TT04). e,  SA-βGal staining  of  TT04 treated 
NSCLC cel lines. f-k, SNAI1 (CRS) and  TWIST1 (CRT) EMT expressing KrasG12D 
driven  mouse lung tumors  mRNA expression  of  OGT (P<0.01  by  One-way  ANOVA 
with Dunnet’s multiple comparison test) (f), O-GlcNAcylation by IHC (g), OGT protein 
by  Western  blot (h, i), and  global  O-GlcNAcylation  of  proteins  by  Western  blot (j,  k) 
compared to KrasG12D alone expressing  mice (n≥5  mice  per  genotype). l-n,  O-
GlcNAcylation  was elevated  pharmacologicaly  with  1.5  mg/mL thiamet-G (TMG) in 
LSL mouse drinking water and tumor burden was assessed by CBCT scans (l), H&E (m), 
and contingency table (P<0.05 by Fisher’s exact) (n). o,p, Ogt mRNA expression (o) and 
tumor burden via CBCT (p) at 10 weeks post-intranasal administration of Ad-CMV-iCre 
(AdCre) in  mice from LSL-Ogt+/+ females crossed  with OgtY/fl males. q,  Tumor free 
survival Kaplan-Meier curves of LSL-KrasG12D mice (n=44 mice; median = 8 weeks post-
AdCre) compared to  EMT/KrasG12D mice (CS-LSL;  n=32;  median  =  2  weeks  post-
AdCre), elevated  O-GlcNAcylation  mice (LSL  TMG;  n=9;   median  =  5  weeks  post-
AdCre), and  OGT  knockout  mice (LSL-OGT–/Y;  n=20;  median  =  15  weeks) (statistical 
analysis  by log-rank test). r,s, IHC for  Myc in  CR,  CRS, and  CRT tumors (r)  with 
quantification (s).  Eror  bars,  mean  ± standard  deviation (s.d.)  Unless stated, P values 
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Figure 2.5 Characterizing  a  novel KrasG12D driven  EMT  mouse  model 
of NSCLC 
a,  25 week time course  of  CRS  mouse  model  with inducible  SNAI1 expression 
monitored  by  gross anatomy, cone-beam computed tomography (CBCT) scans, and 
hematoxylin and eosin (H&E) staining. b,  Doxycycline (DOX) inducible expression  of 
SNAI1 was verified with bioluminescence imaging (BLI) and SNAI Western bloting. c, 
d, CR and  CRS  mouse tumor  CBCT scans (c) and  quantification (d) at  6  months. e, 
Tumor regression  of  CRS  mice  38  weeks  post-removal  of  DOX from  mice  drinking 
water as seen  by  CBCT,  H&E, and  SNAI1 immunohistochemistry (IHC) staining. f, 
Cleaved-caspase3 (CC3) IHC staining with quantification of EMT CRS and CRT mouse 
tumors compared to  CR  mouse lung tumors. g, IHC staining  of  phosphorylated  ERK 
(pERK) IHC in CRS mouse tumors compared to CR mouse tumors. Eror bars, mean ± 
standard deviation (s.d.). P values were derived from an unpaired, two-tailed Student’s t-




Figure 2.6 Inducible  SNAI1 expressing  MEFs  overcome HRASG12D 
induced OIS 
a,  Validation  of the  DOX inducible  SNAI1 expressing  MEFs  by  Western  bloting and 
luciferase reporter (visualized  by  BLI). b-d, Inducible  SNAI1  MEFs  were transduced 
with HRASG12V or vector control with or without SNAI1 expression (± 2µg/mL DOX in 
cel culture media) and relative change in cel number (b; P<0.001 by two-way ANOVA 
folowed  by  Holm-Sidak’s  multiple comparisons test),  SA-βGal staining (c,  d)  were 
measured. Unless stated, eror bars, mean ± s.d. P values were derived from an unpaired, 




Figure 2.7 Gene expression  microarray  analysis  of  EMT  NSCLC 
tumor cels 
a, b, Gene  Set  Enrichment  Analysis (GSEA) enrichment  plots (data sets  obtained from 
the Molecular Signatures Database) were generated using diferentialy expressed genes 
between  CR and  CRS  mice and identified significantly  matching  gene sets involving 







Figure 2.8 Seahorse analysis of glycolytic flux of EMT NSCLC cels 
a-f, Glycolytic activity, capacity, and reserve  was  determined in real-time  using the 
Seahorse extracelular flux analyzer for  vector, Twist1, and loss  of function Twist1 in 
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A549 (a-c) and  PC9 (d-f) cels.  Eror  bars,  mean  ± s.d.  P  values  were  derived from an 






Figure 2.9 The EMT correlates with the HBP and is overexpressed in 
human NSCLC 
a, Gene co-expression data of lung adenocarcinoma patient tumors with co-expression of 
EMT and  HBP  genes (Red – tendency towards  mutualy exclusivity;  green – tendency 
towards co-expression;  yelow – significance P<0.05). b, c, Human tissue  gene 
expression from  Medisapiens In  Silico Transcriptomics (IST) from  60  healthy tissues; 
significant  gene expression  of GFPT2 (b) and UAP1 (c)  were found in  mesenchymal 
stem cels (purple arows). d, Genes encoding steps of the HBP in lung adenocarcinoma 
patient tissue samples from  20 individual  patient  data sets  using the  Oncomine 
compendium of cancer transcriptome profiles. e, UAP1 mRNA expression of HeLa cels 
with or without SNAI1 DOX induced expression (±2 µg/mL DOX in cel culture media). 
f-i,  mRNA expression  of the HBP  genes  by  qPCR in vitro with  EMT expressing  non-
	 48	
cancer HBEC cels (f), the NSCLC cel lines H460 (g) and H358 NSCLC cel line (h), 
and in vivo autochthonous lung tumor  mouse  models  with and  without  DOX inducible 
expression of SNAI1/KrasG12D (i). Eror bars, mean ± s.d. P values were derived from an 







Figure 2.10 The HBP is critical for senescence of normal lung cels and 
the LSL lung tumor mouse model 
a-d, Genetic inhibition of the HBP with knockdown of GFPT2 and UAP1 as shown by 
mRNA(a) and  protein levels (b) and resulting cel  number change  per field  of  view 
(FOV; c) and  SA-βGal staining (d) (statistical analysis  by  One-way  ANOVA  with 
Dunnet’s multiple comparison test). e-g, SA-βGal staining in HBEC cels upon 48 hour 
pharmacological inhibition  of the  HBP  with  50µM  6-diazo-5-oxo-L-nor-leucine (DON) 
and  Azaserine (Aza) (e) and  metabolic rescue  by supplementation  with  glucosamine 
(GlcN; f) or N-acetylglucosamine (GlcNAc; g) (statistical analysis by One-way ANOVA 
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with Dunnet’s multiple comparison test). h, i, Bright field images of SA-βGal staining 
using genetic siRNA (h) and pharmacological DON (i) inhibition of the HBP. j, Breeding 
schematic of the Lox-Stop-Lox KrasG12D (LSL) model with DOX inducible lung specific 
expressing SNAI1 (CS) and Twist1 (CT) mouse models to generate DOX inducible EMT 
models  with conditional expression  of KrasG12D upon intranasal administration  of  Ad-
CMV-iCre (AdCre)  virus.  Unless stated, eror  bars,  mean  ± s.d.  P  values  were  derived 






Figure 2.11 Inhibition  of the  HBP in  human  NSCLC cel lines reduces 
cel viability through senescence and/or apoptosis 
a, b, Genetic knockdown in A549 and H358 cels with siRNA targeting GFPT2 (a) and 
UAP1 (b) confirmed on the protein level by Western blot. c-d, Clonogenicity measured 
by crystal  violet stained colonies  on  10 cm  dishes (c) and cel  viability analyzes  by 
CyQuant  Assay (d)  of  A549 cels after  48  hours  of  pharmacological inhibition  of the 
HBP with DON treatment. e-f, qPCR (e) Western blot (f, g) for markers of senescence in 
3  NSCLC cel lines  upon  48  hour treatment  of  DON.  Unless stated, eror  bars,  mean 







Figure 2.12 Inhibition  of the  HBP in vivo abrogates tumor  growth  and 
promotes senescence phenotypes 
a-d, H358  NSCLC cels (8x106)  were injected into  ~5  week  old athymic  nude female 
mice.  Within the first  week (visible tumors  of  ~50  mm3),  mice  were treated  with  20 
mg/kg/week  DON and  were assessed for tumor  growth (P<0.01  by long-rank test; a), 
tumor  mass (b), and  SA-βGal staining (c)  with  no  noticeable toxicities to the  mice 
measured by body mass (d) (P>0.05 by Two-way ANOVA) over a 5 week period. e-h, 
Likewise, A549 NSCLC cels (1x106) were injected into ~5 week old athymic nude male 
mice and  within the first  week (visible tumors  of  ~50  mm3)  mice  were treated  with  20 
mg/kg/week DON and were assessed for tumor size (e), tumor volume (n≥12 tumors per 
arm; P<0.0001  by two-way  ANOVA folowed  by  Holm-Sidak’s  multiple comparisons 
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test; f), tumor growth (P<0.0001 by log-rank test; g), and markers of senescence (h) over 
a 3 week period. i, CS-LSL mouse mass with and without DON treatment over 4 weeks 
(P>0.05  by  Two-way  ANOVA). j,  k,  CT-LSL contingency table (P<0.05  by  Fisher’s 
test) and CBCT scans (k) at 5 weeks post-AdCre. Unless stated, eror bars, mean ± s.d. P 







Figure 2.13 SNAI1 expression correlates with O-GlcNAcylation.  
a-c, Immununofluoresence (IF)  of  SNAI1 and  O-GlcNAc co-expressing  A549  NSCLC 
cels (with elevated  O-GlcNAc cytoplasmic immunopositive foci) (a),  48  hour  DOX 
inducible SNAI1 expressing MEFs (b), and stable knockdown of SNAI1 in H358 NSCLC 




 Figure 2.14 N- and O-Linked glycosylation and the HBP in novel EMT 
mouse models of lung cancer 
a, CR, CRS, and CRT mouse tumors were assessed for N-glycosylation with the terminal 
glycosyl/mannosyl  binding lectin (concanavalin  A [conA]) and specificity  of the conA 
lectin  was assessed  by  bloting  with  200  mM  Mannose. b-e, LSL  mouse tumors  were 
compared to  CS-LSL (b, c) and  CT-LSL (d, e)  mouse tumors for  O-GlcNAcylation, 






Figure 2.15 Inhibition  of  N-glycosylation  with tunicamycin  does  not 
induce senescence phenotype, unlike inhibition of the HBP with DON 
a-e, Normal (a) and NSCLC cels (b-d) were treated with either tunicamycin (TUNI, 0.5 
or 1 µg/µL) or DON (5 or 10 µM) and bloted with concanavalin A (ConA) to assess N-
	 57	
link glycosylation occupancy; ConA was assessed for specificity by competitive bloting 
with  200  mM  mannose. e-h,  Senescence  morphology  was seen in  DON (5  or  10 µM) 




Figure 2.16 EMT elevates O-GlcNAcylation and is required to suppress 
senescence by stabilizing oncogenes like c-Myc 
	 59	
a, SNAI1 expression A549 cels and the co-expression of O-GlcNAc transferase (OGT) 
and c-Myc  by  Western  blot. b, c,  Senescence  morphology as seen  with  phase contrast 
microscopy (b) and  destabilization  of c-Myc  by  Western  blot (c)  of in  NSCLC cels 
treated for  48  hours  with the  OGT inhibitor  TT04. d, e, O-GlcNAc reduction  with 
treatment DON in NSCLC A549 cels in vitro (48 hours; d) and A549 xenograft in vivo 
(3  weeks, e). f,  g, Clonogenic assay (f) and c-Myc levels  by  Western blot (g) after  48 
hour transient genetic ablation of OGT in A549 cels. h, Cel proliferation over 1 week in 
inducible tamoxifen OGT knockout in MEFs (P<0.0001 by Two-way ANOVA). i, EMT 
models of KrasG12D driven lung cancer were enriched for diferentialy expressed genes 
related to MYC programs (data sets obtained from the Molecular Signatures Database). 
j,k,  Western  blots  of  SNAI1 and c-Myc levels in  A549 and  H358  NSCLC cel lines 
treated  with  pharmacological inhibitor  of the  HBP (10 µM  DON) (j) and  SNAI1 
overexpressing expression cels (k). l, c-Myc IHC in  SNAI1 expressing autochthonous 
CS-LSL mouse tumors compared to LSL KrasG12D alone SNAI1 increased c-Myc levels 
in vivo assessed with c-Myc. Unless stated, eror bars, mean ± s.d. P values were derived 




Chapter 3: Materials and methods 
 
3.1 Cel lines and drug treatments 
The  human  non-smal cel lung cancer (NSCLC) cel lines (H460 and A549) and 
embryonic kidney cel lines, (HEK-293T and Gryphon) were obtained from ATCC and 
grown in  media as recommended.  The  NSCLC cel lines (H358 and  H23) and  human 
bronchial epithelial cel (HBEC-3KT) line  were  gifts from  Steve  Baylin.  OgtY/fl MEFs 
were generated and maintained as previously described189. Inducible SNAI1 MEFs were 
isolated from  E13.5 embryos and  propagated as  described  previously177.  MEFs  were 
grown for two population doublings and then frozen for future experiments. MEFs were 
grown in DMEM supplemented with 10% fetal calf serum. Al cel lines were checked by 
short tandem repeat  profiling and  mycoplasma testing services  of the Johns  Hopkins 
Medicine  Genetic  Resources  Core  Facility.  Cels  were treated  with the appropriate 
inhibitor for 48 hours prior to analysis using the folowing compounds: 6-Diazo-5-oxo-L-
norleucine (D2141, Sigma), TT04 (ST045849, TimTec), Thiamet-G (4390, Bio-Techne), 
Tunicamycin (T7765, Sigma), and Azaserine (A4142, Sigma). 
 
3.2 PCR genotyping  
DNA was isolated from mouse tails by boiling in 100 µL Solution A (0.5M EDTA pH8 
and 10M NaOH in diH2O) for one hour and then adding Solution B (Tris HCl pH 8 in 
diH2O). The CCSP-rtTA (C), tetO7-Kras
G12D (R), Twist1-tetO7-luc (T), and LSL-Kras
G12D 
(LSL) transgenic lines were screened as described previously20. The SNAI1-tetO7-luc line 
was  detected  with the folowing  primers:  SNAI1-Luc.S2  59- 
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CCTTATGCAGTTGCTCTCCAG -39 and  SNAI1-Luc.AS2  59- 
GCTTGCCTATGTTCTTTTGGA -39.  DNA  was amplified  using  PCR and  PCR 
products were resolved on a 2% agarose gel. 
 
3.3 Transgenic mice  
The human SNAI1-6SA cDNA153 was PCR cloned into the bidirectional tetO7 vector S2f-
IMCg190 at EcoRI and NotI sites, replacing the eGFP ORF.  The resultant construct, 
SNAI1-6SA-tetO7-luc, was sequence confirmed, digested with KpnI and XmnI to release 
the  bidirectional transgene and then  used for injection  of  FVB/N  pronuclei  by the 
Stanford Transgenic Facility. We obtained one founder after screening by tail genotyping 
using PCR as described below. This founder was mated to CCSP-rtTA mice to screen for 
inducible SNAI1-tetO7-luc expression and was used for al the experiments in this study. 
 
We  use the β-actin-rtTA, CCSP-rtTA, tetO7-Kras
G12D, Twist1-tetO7-luc, and LSL-
KrasG12D single transgenic lines20,182,191,192 and  bred these  mouse lines to  generate the 
appropriate  double and triple transgenic  mouse lines. SNAI1, Twist1, and/or KrasG12D 
expression was activated in the CS, CT, CR, CRS, CRT, CS-LSL, and CT-LSL lung lines 
by administering doxycycline (DOX, Sigma) to the drinking water [2 mg/mL] starting at 
the age  of  4-5  weeks and  was changed  with fresh  DOX  weekly.  The conditional LSL- 
KrasG12D lines were activated by intranasal delivery of Ad-CMV-iCre (no. 1045, Vector 
Biolabs)182.  DON (D2141, Sigma)  was administered intraperitoneal (I.P.) to  mice [20 
mg/kg] BID and Thiamet-G (4390, Bio-Techne) was administered [1.5 mg/mL] in mouse 
drinking water changed every 3 days. Al procedures were performed in accordance with 
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Stanford Administrative Panel on Lab Animal Care (APLAC) and Johns Hopkins Animal 
Care and Use Commitee (ACUC) protocols and animals were housed in a pathogen- free 
environment.  
 
3.4 LSL-KrasG12D Ogt knockout mice 
The  Cre conditional  X-linked OGTfl/fl mouse line  was  genotyped and  mouse lines  were 
maintained as  previously  described189.   Male LSL-KrasG12D (LSL)  mice  with  wildtype 
OGTY/+ were crossed  with female  homozygous OGTfl/fl resulting in al  homozygous 
OGTY/fl males.  Only  male  LSL OGTY/fl mice  were  used in experiments, as  males  were 
homozygous for the floxed alele compared to  hemizygous females. Intranasal 
administration  of  Ad-CMV-iCre (no.  1045,  Vector  Biolabs)  was  used to infect lung 
epithelial cels, simultaneously inducing KrasG12D expression while knocking out OGTY/–. 
OGT knockout was validated by qPCR from frozen lung tissue samples. 
 
3.5 Smal animal imaging and quantification 
Cone-beam computed tomography (CBCT)  were  performed  on an "in-house standalone 
system”193. The animal was placed in a rotatable animal stage lies between the stationary 
and  paralel  opposed  x-ray source and the  detector  panel."  Mice  were screned serialy 
every  1–5  weeks folowing  doxycycline activation and/or intranasal adenoviral  Ad-
CMV-iCre (no.  1045,  Vector  Biolabs) and images  were reviewed  by a  board certified 
radiation oncologist (PTT). No atenuation corection or partial volume corections were 
applied. CBCT images were reviewed by a board certified radiation oncologist (PTT) for 
quantification at 6 months post-DOX. 
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3.6 Mouse xenograft model  
Female athymic  nude  mice  4–5  weeks  old  were  purchased from  Harlan  Laboratories. 
Mice  were  maintained  under  pathogen-free conditions and  given food and  water ad 
libitum in accordance  with  guidelines from the Johns  Hopkins  Animal  Care and  Use 
Commitee.  1x1010 A549 cels  or  8x1010 H358 cels in  100  mL  of  RPMI and  Matrigel 
(BD  Biosciences)  mixed  1:1  were injected subcutaneously in right and left flank.  Mice 
were split into  DON treated and  untreated  groups (n≥16 tumors) and tumor 
measurements  were taken every  3 days for  3-5  weeks.  DON (D2141, Sigma)  was 
dissolved in sterile diH2O and was administered once a week intraperitoneal (I.P.) within 
one week post tumor injection (or when smal tumors were first visible,~50 mm3.) for 3-5 
weeks.  Mice  were euthanized  by  CO2 when tumors reached the  volume  of  500mm
3 
(1,000mm3 per mouse). 
 
3.7 SYBR-green quantitative RT–PCR  
Total  RNA  was isolated from tissue  using  TRIzol  RNA Isolation  Reagent (Life 
Technologies) according to the manufacturer protocol. cDNA was generated from 1 µg of 
total  RNA  using the iScript cDNA synthesis  kit (Bio-Rad). cDNA  was amplified  with 
iTaq™  Universal  SYBR®  Green  Supermix (Bio-Rad)  using the  CFX384  Touch  Real-
Time  PCR  Detection  System (Bio-Rad)  with the  C1000  Touch™Thermal  Cycler (Bio-
Rad) for  up to 40 cycles.  PCR reactions  were  performed in at least triplicate in a final 
volume of 10 µL. 
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For every sample, the diference in cycle threshold (∆Ct) values were determined as the 
diference  between the  Ct  value  of a specific transcript and the  Ct  value  of  18s rRNA, 
serving as the  housekeeping control  messenger  RNA, and relative transcript levels (for 
example, treated versus untreated) were calculated based on 2(–∆∆Ct) with ∆∆Ct = ∆Cttreated 




ONCOGENE INDUCED SENESENCE GENES 
INK4B (p15)  F AAGCTGAGCCCAGGTCTCCTA 
   R CCACCGTTGGCCGTAAACT 
INK2A (p16)  F CTAGACGCTGGCTCCTCAGTA 
   R GGGTTTTCGTGGTTCACATCC 
CDKN1A (p21) F CGATGGAACTTCGACTTTGTCA 
   R GCACAAGGGTACAAGACAGTG 
CDKN1B (p27) F ATCACAAACCCCTAGAGGGCA 
   R GGAGCCCCAATTAAAGGCG 
TP53 (p53)  F CCAGGGCAGCTACGGTTTC 
   R CTCCGTCATGTGCTGTGACTG 
SPRY2  F CCTACTGTCGTCCCAAGACCT 
   R GGGGCTCGTGCAGAAGAAT 
IL6   F ACTCACCTCTTCAGAACGAATTG 
   R CCATCTTTGGAAGGTTCAGGTTG 
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IL8   F ACTGAGAGTGATTGAGAGTGGAC 
   R AACCCTCTGCACCCAGTTTTC 
 
HEXOSAMINE BIOSYNTHESIS PATHWAY GENES   
GFPT1  F ACAATCGGGAAAGTCAAGATACC 
   R CACCAATCAACAGAGGGCTAC 
GFPT2  F AGACACACTTCGGCATTGC 
   R TTGGCGATGGTCTCTGTATCT 
GNPNAT1  F ACTCCTATGTTTGACCCAAGTCT 
   R TCTGTTAGCTGACCCAATACCT 
PGM1   F CCAAACCGACTGAAGATCCGT 
   R CATGTTTCGATCCCCATCTCC 
PGM2   F GAGGCAGTGAAACGACTAATAGC 
   R CTGTCCCAAACTCCATTCGGG 
PGM5   F AGCGACGGCAGGTACTTTAG 
   R CTGTCCAATAATCAGTCGTCCAA 
UAP1   F AATGACCTCAAACTCACGTTGT 
   R GCTCTGCATAAAGTTCTACCTGT 
 
EMT GENE 
SNAI1   F TCTAGGCCCTGGCTGCTACA 





ONCOGENE INDUCED SENESENCE GENES 
Ink4B (p15)  F CCCTGCCACCCTTACCAGA 
   R CAGATACCTCGCAATGTCACG 
Ink2a (p16)  F GCTCAACTACGGTGCAGATTC 
   R GCACGATGTCTTGATGTCCC 
Cdkn1a (p21)  F CGAGAACGGTGGAACTTTGAC 
   R CCAGGGCTCAGGTAGACCTT 
Cdkn1b (p27)  F TCTCTTCGGCCCGGTCAATC 
   R CTCTCCACCTCCTGCCACTC 
Trp53 (p53)  F CCCCTGTCATCTTTTGTCCCT 
   R AGCTGGCAGAATAGCTTATTGAG 
Spry2   F TCCAAGAGATGCCCTTACCCA 
   R GCAGACCGTGGAGTCTTTCA 
Il6   F TAGTCCTTCCTACCCCAATTTCC 
   R TTGGTCCTTAGCCACTCCTTC 
   
HEXOSAMINE BIOSYNTHESIS PATHWAY GENES      
Gfpt1   F GCCAACGCCTGCAAAATCC 
   R CCAACGGGTATGAGCTATTCC 
Gfpt2   F ATGTGCGGAATCTTTGCCTAC 
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   R AGACCCCTGATAAGGGTTTCG 
Gnpnat1  F TCGTTAGTGACGAGTGCAGAG 
   R TTTGTGGTAGACATTCAAGGGTG 
Pgm1   F CAGAACCCTTTAACCTCTGAGTC 
   R CGAGAAATCCCTGCTCCCATAG 
Pgm2   F CCGCTTCTACATGACCGAGG 
   R GATGATGCAAGATACGGCAGG 
Pgm5   F GGACGGCTACTGAGATCGTG 
   R GGACCTCCATTGGCAACATTAAA 
Uap1   F GGAGTCTCATATCCCAAGGGC 
   R TGTTCTGCCGCTGGTCATTAT 
 
3.8 Immunoblot, immunofluorescence, and lectin blot analysis  
Cels  were lysed  on ice for  60  min in  RIPA lysis  bufer (R0278,  Sigma) supplemented 
with Protease Inhibitor Cocktail (P8340, Sigma), Phenylmethylsulfonyl fluoride (PMSF; 
10837091001,  Sigma), β-hexosamindase inhibitor (376820,  Milipore), and  Thiamet-G 
(4390,  Bio-Techne) inhibitors and clarified  by centrifugation.  Protein concentrations 
were  determined  by  Pierce™660nm  Protein  Assay (Bio-Rad).  Equal aliquots 
coresponding to  20 to  60 µg  of  protein  were resolved  on  6-12%  SDS-polyacrylamide 
gels and transfered to PVDF or nitrocelulose membranes. Antigen detection was caried 
out  with the antibodies against the folowing  proteins:  Actin (C-11,  Santa-Cruz 
Biotechnology (SCBT),  1:5000),  Twist1 (TWIST2C1a,  SCBT,  1:100),  SNAI1 (NBP1-
80022, Novus, 1:2000; H-130, SCBT, 1:500), GFPT2 (EPR19095, Abcam, 1:500), UAP1 
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(EPR10259, Abcam, 1:500), c-Myc (Y69, Abcam/Epitomics, 1:10000), p21 (12D1, Cel 
Signaling  Technology (CST),  1:1000),  p53 (no.  9282,  CST,  1:1000),  OGT (DM-17, 
Sigma Aldrich, 1:2000), O-GlcNAc (CTD110.6, 1:2000), and cleaved caspase 3 (9664S, 
CS). After washing, coresponding anti-mouse IgG (GE Healthcare, 1:2500), anti-rabbit 
IgG (GE  Healthcare,  1:2500), and anti-rabbit IgM (Sigma,  1:2500)  peroxidase-
conjugated secondary antibodies were used. Antigen-antibody complexes were visualized 
by  Amersham electrochemiluminescence (ECL  detection system;  GE  Healthcare). 
CTD110.6 specificity for O-GlcNAc was tested by bloting with or without 200mM N-
Acetylglucosamine (GlcNAc;  Sigma).  Relative  O-GlcNAcylated  protein levels  were 
measured  by analyzing the  bands  density  using ImageJ 
(htp:/imagej.nih.gov/ij/download.html) then  normalized to the  density  of actin.  Al 
experiments  were  performed in triplicate and average relative fold changes  were 
calculated. 
 
For immunofluorescence,  SNAI1 (H-130,  SCBT,  1:50) and  O-GlcNAc (RL2,  Novus, 
1:200) were incubated at 4° overnight. After washing, Alexa488-conjugated anti-mouse 
(green) and  Alexa594-conjugated anti-rabbit (red) (Invitrogen,  1:300)  were  used as 
secondary antibodies and incubated at room temperature for 30 minutes. DAPI (blue) was 
used as a  nuclear stain and slides  were  mounted in aqueous  mounting  media (Vector 
Laboratories).  
 
For  N-glycosylation analysis, membrane  was  blocked in  3%  BSA in  TBS,  washed in 
TBS, and incubated at  4º  overnight  with Concanavalin  A-HRP lectin (ConA; L6397, 
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Sigma, 0.25ug/ml) in high-salt TBST (HS-TBST; 1M NaCl, TBST). The blot was wash 
extensively in  HS-TBST and  developed  using  ECL  detection system (GE  Healthcare). 
ConA specificity was tested by bloting with or without 200mM mannose (Sigma).  
 
3.9 Histology and immunohistochemistry 
Formalin-fixed  parafin-embedded (FFPE) tissues  were  processed and stained  with 
hematoxylin & eosin (H&E) according to common procedures. Tissues were prepared on 
plus slides antigens, antigen were retrieved with Target Retrieval Solution (S1699, Dako) 
and probed for antigen with the following antibodies: Ki-67 (NCL-Ki67p, Leica, 1:1000), 
p16 (F-12,  SCBT,  1:200),  pERK (4370,  CST,  1:400), cleaved caspase-3 (9664,  CST, 
1:2000),  SNAI1 (NBP-80022,  Novus,  1:200), c-Myc (Y69,  Abcam/Epitomics,  1:500), 
and  O-GlcNAc (RL2,  Novus,  1:200), as  previously  described20,194.  For  pathological 
analysis, a certified  veterinarian  pathologist (BS) reviewed the  disease  burden for each 
mouse.  For immunohistochemistry analysis, immunopositive cels  were counted and 
analyzed from at least 5 diferent fields of view per section from greater (n≥3 diferent 
animals) in total. For SA-β Galactosidase stain, 10µm sections were cut from Tissue-Tek 
cryo optimal cuting temperature compound (OCT; 14-373-65, Fisher Scientific) infused 
frozen lung tissue and staining  was caried  out as  previously  described20.  H&E, tissue 
processing, and c-Myc IHC were performed using the Johns Hopkins Oncology Tissue 




3.10 Viral transduction and siRNA transfection  
Lentivirus was generated by transfecting HEK-293T cels with SNAI1 shRNA constructs 
obtained from the  Broad  RNAi  Consortium  using pLKO.1-shRNA scramble  vector 
(Sigma) as a negative control. H358 NSCLC cel lines were then transduced with virus as 
previously  described20.   Retrovirus  was  produced  using Gryphon™  Amphotropic 
Packaging  Cel  Line (Alele  Biotechnology),  per company’s recommendation.  Early 
passage  MEFs,  non-cancer  HBEC3-KT cels, and  NSCLC cel lines (A549,  H460, and 
H23) were transfected with pWZL-Hygro vector (Ador pWZL- Hygro/SNAI1 constructs, 
for two successive times  over a  36-h  period folowed  by selection, as  previously 
described for  Twist1 cel lines20.  HBEC3-KT cels  were infected  with  OGA  or  green 
fluorescent  protein (GFP) control adenovirus at a  multiplicity  of infection (MOI)  of  50 
for 6 hours, cel lysate were colected 48 hours post-transduction. For siRNA transfection, 
cels were transfected with ON-TARGETplus Non-targeting siRNA #1, Human GFPT2 
SMARTpool siRNA (L-010390-00-0005,  Dharmacon),  Human UAP1 SMARTpool 
siRNA (L-017160-01-0005,  Dharmacon),  or  Human OGT SMARTpool siRNA (L-
019111-00-0005, Dharmacon) for a final concentration 50nM. Samples were analyzed 48 
hours post-transfection. 
 
3.11 Colony formation and proliferation assays  
Cels  were transiently transfected with OGT siRNA and  plated at  500 cels  per  10 cm 
dish.  After  2  weeks, colonies  were fixed and stained  with crystal  violet (0.5% in  95% 
methanol,  Sigma) and stained colonies (defined as ≥50 cels)  were counted. 
Quantification of MEFs was performed as previously described165 by using crystal violet 
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staining and  quantification  by spectrophotometer.  For al  other cel  proliferation 
experiments, CyQUANT® NF Cel Proliferation assay kit (Molecular Probes; Invitrogen 
Corp., USA) was used to minimize influence of mitochondrial metabolism, according to 
the manufacture protocol. 
 
3.12 Senescence associated-β-gal staining  
After  genetic  or  pharmacological treatment,  non-cancer and cancer cels  were  washed 
twice  with  phosphate-bufered saline (PBS) and then fixed  with  PBS containing  2% 
formaldehyde and 0.2% glutaraldehyde for 5 min. The cels were then incubated at 37°C 
overnight with staining solution (no. 9860, Cel Signaling). After incubation, cels were 
washed twice  with  PBS and  viewed  with  bright-field  microscopy.  Cel  number  was 
measured  by analyzing  using the cel count feature  of ImageJ 
(htp:/imagej.nih.gov/ij/download.html).  Al experiments  were  performed in triplicate 
and average relative fold changes were calculated. 
 
3.13 Microarray data processing and analysis 
Total  RNA  was isolated and purified from cels  using  TRIzol  RNA Isolation  Reagent 
(Life  Technologies) as  detailed  by the  manufacture’s recommendation  with tissue 
homogenization. Labeled RNA was hybridized to the Ilumina Mouse WG-6 Expression 
Aray and scanned as  previously  described195. Gene expression  data  were  normalized 
using the Robust Multichip Average in the oligo Bioconductor package at the transcript 
level196 Genes and  gene sets  with  Benjamini-Hochberg197 P  values  below  0.05  were 
considered statisticaly significant. Gene set enrichment analysis was performed using the 
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C2 Curated  Gene  Sets colection from the  Molecular  Signature  Database  3.0 and 
statistical comparisons by Fisher exact test. The microaray data wil be deposited to the 
Gene Expression Omnibus. 
 
3.14 Determining  diferentialy expressed  genes, enriched  gene sets,  and  gene 
ontology 
Non-specific filtering  was  used to remove  genes  with an interquartile range less than 
0.05. To find diferentialy expressed genes between EMT/KrasG12D driven tumors versus 
KrasG12D alone, Significance Analysis of Microaray28 (‘samr’ R package version 2.0) 
was applied  using a two class  unpaired comparison,  minimal Z-score fold change  of 
1.2, and  median false  discovery rate  of  0.05197.  Unannotated transcripts  were  not 
considered. To test whether gene sets were enriched in response to diferent conditions, 
we  used  Gene  Set  Analysis as implemented in the ‘GSA’  R  package  version 1.0329. 
The ‘max mean’ test statistic was used to test enrichment using a two-class comparison. 
Al p-values and false  discovery rates  were  based  on  500–1,000  permutations.  For re-
standardization, a method that combines randomization and  permutation to corect 
permutation values of the test statistic and to take into account the overal distribution of 
individual test statistics, the entire  data set  was  used rather than  only the genes in the 
gene sets tested.  Gene  Ontology for comprehensive  protein evolutionary and functional 




3.15 Measurement of oxygen consumption rate (OCR) and proton production 
rate (PPR) 
Assessment of celular respiration and aerobic glycolysis was performed by measuring 
OCR and PPR with a Seahorse Bioscience XF24 Extracelular Flux Analyzer (Seahorse 
Bioscience, North Bilerica, MA) as previously described198. Briefly, cel lines were 
plated in standard growth media at a density of 4x104 cels per wel 24 hours prior to 
metabolic analysis. To measure OCR, 1 hour prior to metabolic analysis the normal 
growth media was replaced with XF minimal basal medium (Seahorse Bioscience) 
supplemented with 11 mM glucose, 1 mM sodium pyruvate, and 1X GlutaMax (Life 
Technologies, Grand Island, NY). To measure PPR, 1 hour prior to metabolic analysis 
the normal growth media was replaced with XF minimal basal medium (Seahorse 
Bioscience) supplemented with 11 mM glucose and 1X GlutaMax (Life Technologies). 
After changing to respective XF media, cels were incubated at 37°C in a humidified 
atmosphere without CO2. Oligomycin (1 uM), FCCP (400 nM), rotenone (2 uM) and 
antimycin A (2 uM), and 2-deoxy-D-glucose (100 mM) were added serialy to determine 
mitochondrial respiration measurements. Oligomycin (1 uM) and 2-deoxy-D-glucose 
(100 mM) were added serialy to determine glycolytic capacity measurements. Data 
presented are normalized per cel number per wel. 	
	
3.16 Statistics 
Based on previous experience with our KrasG12D transgenic lung cancer mouse models, 
the sample sizes used typicaly reflect three or more individual primary tumors, each 
from diferent mice (that is, biological, not technical replicates). The survival and tumor 
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latency of mouse cohorts was calculated using Kaplan–Meier estimation and compared 
with the log-rank (Mantel–Cox) test. Statistical analysis of pharmacological treatments 
(TMG and DON) and contingency tables were calculated using Fisher’s exact test. 
Statistical analysis of the data was performed using a two-tailed, unpaired Student’s t-test. 
Values are expressed as mean ± standard deviation, where appropriate. Significance is 
noted as P<0.05 unless stated. (*P , 0.05; **P , 0.01; ***P , 0.001). 
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Chapter 4: Discussion 
	
4.1 Intersection of glycobiology and cancer research 
Many of the fundamental discoveries in cancer biology have built upon the field of 
cancer genetics. These historical discoveries are making a real impact in clinics as 
physicians strive to implement “precision medicine”, that is the specific treatment catered 
to the genetic drivers in the patient’s tumor. Furthermore, our understanding of the 
human proteome has helped identify the functional components of the cancer cel. 
Despite these advancements in genomics and proteomics, our understanding of the 
complete set of carbohydrate modifications of cancer, that is to say glycomics, has lagged 
behind due to technological chalenges. However, as the field of glycobiology is 
becoming of increasing appreciation and the tools that we can use to study this field are 
on the rise, we are in an era of great appreciation for how sugar modifications can alter 
the celular signaling and behavior of cancer cels. It is not surprising that over half of the 
literature on O-GlcNAcylation and cancer, for example, has been published just in the 
past three years. This exponential rate of discovery has been due in part to increasing 
interest in the field. As discussed in the introduction, many of the key targets in cancer 
biology are modulated by sugar modifications and these glycosylations provide an 
additional layer of complexity, shedding new light on the fundamental mechanisms of the 
cancer cel. By gaining new insights, it is apparent that we wil discover new methods of 
targeting tumors for the benefit of future patients. At the time of this thesis, the field of 
glycobiology is gaining traction at a time of the revolutionary new cancer 
immunotherapies. Seeing as many of these immunological receptors are glycosylated, I 
	 76	
envision the field of “glycoimmunology” or “immunoglycobiology” to be a rapidly 
expanding field in the near future. 
 
4.2 Future Directions 
There are many next steps that pertain to the research outlined in this thesis: 
1. How does EMT regulate the HBP? The precise transcriptional mechanism by 
which EMT controls the gene expression of the HBP has yet to be elucidated. In 
data not shown here, preliminary data shows that al of the HBP genes contain 
consensus sequences for the EMT transcription factors SNAI1 and TWIST1. 
Preliminary ChIP data did not show direct binding to these predicted binding sites, 
although much more extensive optimization is required. It is also possible that 
there is a mechanism beyond direct EMT TF binding to the promoter regions of 
the genes of the HBP. 
2. Are other EMT TFs O-GlcNAcylated? This is a question that may be easy to 
validate. As discussed in the introduction, SNAI1 was identified to be O-
GlcNAcylated155. This leads to the thought that the EMT-HBP axis discussed in 
this thesis may serve as a positive feedback loop to stabilize SNAI1. It would be 
also interesting to see if the TWIST and ZEB family of EMT TFs are also 
regulated by O-GlcNAcylation. 
3. What is the role of c-Myc O-GlcNAcylation in OIS suppression? The oncoprotein 
c-Myc was demonstrated to be elevated via the EMT-HBP axis in this thesis. The 
conclusion is logical that the EMT-HBP axis is probably leading to the direct O-
GlcNAcylation and stabilization of c-Myc. However, it is unclear if this 
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corelation is necessary for suppression of OIS. Experiments may be done to 
inhibit the glycosylation or expression of c-Myc to see if O-GlcNAcylated c-Myc 
is required for acceleration of tumorigenesis. 
4. What are other O-GlcNAcylated targets that are elevated in response to the EMT-
HBP axis? From reviewing the data, it is apparent that there are multiple O-
GlcNAcylated proteins/bands that are elevated during EMT. As mentioned in this 
thesis, c-Myc is one of those targets. However, it wil be interesting to identify 
other EMT-HBP axis specific targets to understand the mechanism better. Mass 
spectroscopy technology could possibly identify these O-GlcNAcylated targets, as 
people in the field are curently optimizing this protocol. It would be very 
appealing to see if immunological receptors such as PD-L1 are also modulated 
this way to provide cancer some type of immunological resistance. 
5. Does the EMT-HBP axis engender radioresistance? There is some evidence to 
suggest the HBP and O-GlcNAcylation have efects on DNA damage response. 
Thus next step wil be to assess if the EMT-HBP axis is suficient to provide 
radiation therapy resistance to tumors. These experiments can also be assessed in 
our in vivo mouse models described in this paper. Likewise, it wil be of 
importance to see if the inhibition of the HBP in EMT/mutant KRAS lung cancer 
wil sensitize the tumors to radiation therapy. 
6. Do more specific inhibitors of the HBP demonstrate the same efect? There are 
curently laboratories synthesizing novel compounds to inhibit the HBP (UAP1 
inhibitor). Seeing as UAP1 was one of the significantly altered genes expressed in 
EMT mice compared to mutant Kras expressing mice alone, it may be interesting 
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to see if targeting UAP1 yields the same efect as the dirty inhibitors DON and 
Azaserine regarding anti-tumor response and induction of senescence programs. 
 
4.3 Summary 
The data presented in this thesis provide novel insight into cancer biology. It uniquely 
ties together the fields of epithelial plasticity, senescence, glycobiology, and lung cancer. 
The research outlined demonstrates a novel mechanism by which an epithelial plasticity 
program alters cancer metabolism to accelerate the formation of lung cancer by 
suppressing oncogene induced senescence. The novelty of our laboratory definitely 
comes from our lab’s history of working with novel advanced autochthonous mouse 
models of mutant KRAS and EMT. The flexibility of the system alowed us to also cross 
in the OGTfl/fl mouse model normaly utilized in cardio and neuroscience research. This 
provided a unique opportunity to study the phenomenon not only in vitro, but most 
importantly in vivo in a cancer mouse model that closely recapitulates the autochthonous 
formation of lung tumors in humans. We also demonstrated through this mechanism that 
inhibition of this pathway leads to stunted tumorigenesis as wel as tumor regression in 
vivo. Overal, this thesis provides evidence for a novel EMT-HBP axis that is implicated 
in mutant KRAS lung tumorigenesis and future studies wil need to be conducted to fine-
tune the precise mechanism and identify key players by which this novel pathway 
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RESEARCH & WORK EXPERIENCE: 
➤ Johns Hopkins University School of Medicine Celular and Molecular Medicine    
  (Baltimore, MD)           2012-2013 
• Dr. Sara Sukumar Lab: Celular signaling in the tumor microenvironment; induction of 
angiogenesis in breast cancer 
• Dr. Wiliam Nelson: Novel function, localization, and expression of the epigenetic Methyl 
Binding Domain 3 (MBD3), 
• *Dr. Phuoc Tran: Studied Epithelial-Mesenchymal Transition transcription factors TWIST1 
and SNAI1 in both in vitro cel and in vivo autochthonous murine tumor model setings 
(*current laboratory for doctoral thesis) 
➤ Milennium: The Takeda Oncology Company - Global Medical Afairs  
   (Boston, MA)        Summer 2012 
• Analyzed and contributed edits to multiple publications for pharmaceutical scientists and 
physicians 
• Worked with design team and physicians to create a more intuitive/artistic rendition of 
Orteronel (TAK-700) drug MOA 
➤ Fairfield University - Cancer Biology Research, Dr. Sheley Phelan  
  (Fairfield, CT)              Summer 2011-2012 
• Aim was to determine upstream effects of growth factors, MAP kinases, PKC, and H2O2 on 
Peroxiredoxin expression 
• Researched breast cancer’s relationship to Peroxiredoxin (PRDX) antioxidant gene family 
• This research is important because oxidative stress is associated with cel death, cancer, and 
other degenerative diseases 
➤ Fairfield University - Molecular Biology Research, Dr. Anita Fernandez 
(Fairfield, CT)                      Fal 2010 
• Aim was to identify gene segment and sequence related to Piwi-2, Beta-Catenin, Sine Oculus 
in Dugesia tigrina 
• Identified sequences for β-catenin and Sine oculis in D. tigrina by developing PCR primers 
➤ University of Hawai‘i Hilo - Life Sciences C. elegans Researcher  
(Hilo, HI)               Summer 2010 
• Researched protocol for inducing male C. elegans and gender differences related to heat 
shock proteins 
• Worked with the United States Department of Agriculture to test medical compound on male 
cultures 
➤ University of Hawai‘i Mānoa - Biomedical Research Associate 
 (Honolulu, HI)             Summer 2009 
• Worked under the mentorship of the late Dr. Tom Humphreys, School of Medicine Institute 
for Biogenesis Research 
• Mapped hemichordate regeneration in P. flava in its application to chordate neurogenesis, 
POU domain, and stem cels 
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GRANTS & RESEARCH SUPPORT: 
NIH F31 Predoctoral Individual National Research Service Award   
(Over 3 Years: $128,028)               2013-2016 
“Mechanisms of TWIST1-induced sorafenib resistance in liver cancer” Predoctoral 
Felow 
- Youngest PhD student in program 20 year history to receive F31 grant, First Native 
Hawaian at Johns Hopkins School of Medicine 
- Ruth L. Kirschstein NRSA for Individual Predoctoral Felowships to Promote Diversity in 
Health-Related Research 
- Received this F31 from the National Cancer Institute of the National Institutes of Health; 
Award Number F31CA189588. 
 
American Association for Cancer Research-Takeda Oncology Scholar in Training 
Award  
($1,500)             2016 
- Selected by the AACR Awards commitee, competing against over 1,200 applicants from 
around the world 
- AACR Scholar-in-Training Awards are highly competitive and are presented to fewer than 
10 percent of applicants 
- “Recognizes outstanding young cancer investigators presenting meritorious papers at the 
AACR Annual Meeting” 
 
American Association for Cancer Research MICR Minority Scholar in Cancer Research 
Award  
($1,500)      2015 
- Selected by AACR’s Minorities in Cancer Research (MICR) Council to receive this 
Research Award 
- Sponsored by the National Cancer Institute to support my atendance at the 2015 AACR 
Annual Meeting 
- I competed against graduate students, medical students, residents, clinical/postdoctoral 
felows, and junior faculty 
 
Cold Spring Harbor Laboratory - National Cancer Institute Travel Award  
(Travel Grant: $150)             2014 
“Snai1 accelerates Krasg12d driven lung tumorigenesis by overcoming oncogene-induced 
senescence” 
- This travel award was made possible by a NCI grant awarded to the Cold Spring Harbor 
Laboratory 
- This grant provided financial assistance for graduate students in the life sciences to atend 
this CSHL conference 
 
Johns Hopkins Alumni Association Grant for the Biomedical Scholars Association  
(Grant: $1,500)               2014 
“A SHaRP Way to Engage Early Baltimore Biomedical Scholars” 
- Selected for a competitive grant to provide interactive laboratories to underrepresented 
minority high school students 
- Students in the MERIT program are prepared for their dreams of becoming biomedical 
researchers and physicians 
- Grant was selected for “holding the most promise for enhancing academics, extracurricular 
activities, student life, and/or community involvement at JHU” 
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Fairfield University Magis Scholar - Highest Institutional Scholarship  
(Scholarship: $66,000 Grant: $1,500)   2009-2012 
“Overexpression of the Peroxiredoxin Family of Antioxidant Proteins in Breast Cancer” 
- The grant portion of this scholarship alowed me to conduct summer research and provided 
financial assistance to atend the 103rd Annual Meeting of the American Association for 




➤ Peer Learning Group (PLG) Instructor at Fairfield University (Fairfield, CT)  2010-2012 
• Prepared lessons for general biology (BI 171, 172) to complement weekly lectures conducted 
by biology faculty 
• Mentored first year biology students, guiding them along their adjustment to colege life 
➤ Fairfield University Peer Tutoring Program Tutor (Fairfield, CT)       2009 - 2012 
• Provided one-on-one tutoring sessions from Department of Academic and Disability Support 
Services 
• Tutored Japanese 110, 111, 210, & 211 as wel as Chemistry 11 &12 
➤ Modern Languages Oral Practice Sessions Instructor (Fairfield, CT)    2009 - 2010 
• Trained in and learned to implement the Dartmouth Method of language acquisition 
• Prepared three weekly hour-long Japanese lessons to supplement material covered in JPN 
110, 111, 210, & 211 courses 
 
COMMUNITY SERVICE / VOLUNTEERING / EXTRACURRICULARS: 
➤American Association for Cancer Research (AACR) - Associate Member Council  
(USA) 2015-2018 
• Selected among ~100 graduate and medical students, residents, clinical and 
postdoctoral felows from across the world 
• Advocates for and represents over 15,000 Associate Members of the AACR for a 3 
year leadership position 
➤ National Raly for Medical Research Hil Day and Early Career Scientist Hil Day 
(Washington, D.C.) 2015-2016 
• Invited twice to Washington, D.C. to meet with United States Senators and 
Representatives to advocate future of NIH funding 
• Advocated alongside survivors, scientists, and health care professionals to discuss the 
importance of biomedical research 
➤Volunteer at The Hackerman-Patz Patient and Family Pavilion at Johns Hopkins 
(Baltimore, MD) 2014-2016 
• Volunteered at the Johns Hopkins Hospital Sidney Kimmel Comprehensive Cancer 
Center afiliated patient housing 
• Provided hospitality and support to patients and families enhancing the Pavilion's 
welcoming, home-like environment 
• Assisted with weekly programming including hosting, seting up, and cleaning up 
weekly dinners for cancer patients 
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➤Johns Hopkins University Biomedical Scholars Association - Executive Board  
(Baltimore, MD) 2014-2016 
• Served as the BSA Executive Board Community Service and Outreach Oficer 
• Director of the Science, Health, and Research Partnership (SHaRP) Initiative 
engaging high school biomedical scholars 
➤Medical Education Resources Initiative for Teens (MERIT) Mentoring Program 
(Baltimore, MD) 2014-2016 
• Served on the 2015 MERIT Education Curiculum Development team as a biomedical 
content coordinator 
• Assisted in developing biomedical curiculum and research experience for Baltimore 
County high school students 
➤Embajadores de Salud Volunteer  
(Baltimore, MD) Summer 2014 
• Participated in weekly work out sessions with minority latino community members to 
promote health and wel being 
• Communicated with 15+ hispanic members of the community while training for 5K 
run despite having no Spanish language training 
➤The Maryland School for the Blind Outreach Volunteer 
 (Baltimore, MD) 2012-2014 
• Aided in arts and crafts with middle school to colege level students with visual and/or 
hearing impairments 
• Designed lessons to promote enhancement of tactile and auditory sensation in an 
engaging manner through the arts 
➤ Mentoring at Fairfield University 
(Fairfield, CT) 2009-2012 
• First Year Student Mentor (FYE Program), taught a formal class helping new students 
adjust to colege life 
• Mentored first year minority and first generation students as a Cura Personalis 
Mentor; Mentor of the Year Award 
➤ Leader of Ignatian Solidarity Corps International Service and Immersion 
Program (Kingston, Jamaica) 2011-2012 
• Missionaries of the Poor Bethlehem Center: Helped feed, bathe, and care for mentaly 
and physicaly impaired children 
• The Home for the Destitute and Dying: Worked at home for the elderly run by Mother 
Teresa's Missionaries of Charity 
• Served as teachers’ aide for Pre-Primary School/Health Clinic located in an 
economicaly poor area built on a city dump 
• Selected to lead the 2011-2012 Ignatian Solidarity Corps International Service Trip to 
Kingston, Jamaica	
➤ Ignatian Solidarity Corps International Service and Immersion Program  
(Punta Gorda & Delores, Belize) 2010-2011 
• Participated in a 3 month program in preparation for service trip learning Belizian 
culture, politics, economics, etc. 
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• Filmed, directed, and edited a 30 minute documentary on the 2011 International 
Service Trip to Belize 
• Built a Huricane shelter, renovated an HIV/AIDS Children Center, engaged with 
locals, worked in Mayan vilage 
• Lived in solidarity with Mayan vilagers and presented English and Mathematics 
lessons at vilage elementary school 
➤ Hui ‘Ohana ‘O Hawai‘i Founder and President  
(Fairfield, CT) 2010-2012 
• Led an organization that welcomed members from al cultures to learn about the local 
and Native traditions of Hawai‘i 
• Worked with Hawaian Tropic Sunscreen and Coleges Against Cancer to distribute 
hundreds of free sunscreen samples 
• Organized a culturaly authentic Lū‘au with hula lessons, authentic Hawai‘i cuisine, 
and self-produced educational video 
➤ Ofice of Residence Life - Resident Assistant 
(Fairfield, CT) 2010-2012 
• Responsible for >200 sophomore colege students and promoted healthy living with 
weekly yoga sessions, group morning jogs, etc. 
• 2011 Residence Life Programer of the Year for planning numerous intelectualy and 
socialy engaging programs  
➤ USA Swimming National Athlete Representative/State Athlete Representative  
(USA) 2006 - 2010 
• Selected Nationaly to represent the swimmer athletes on the Convention Education 
Commitee for USA Swimming 
• Planned, moderated, and led national convention sessions on technology safety, social 
media, sports energy drinks, etc. 
➤ Fairfield University Rotaract Club 
(Fairfield, CT) 2010 - 2012 
• Helped with the on campus blood drive in sponsorship with the American Red Cross 
• Was involved with the Purple Pinky Project fundraiser to raise money to eradicate 
polio around the world 
➤ Fairfield University Varsity Swimming and Diving Team 
(Fairfield, CT) 2008 - 2009 
• Set 6 individual and 2 relay Fairfield University Program Records; MAAC 
Conference Swimmer of the Week 
• Multiple Time Conference Championship Medalist, Won 19 out of 24 dual meet races 
 
